WO2013047864A1

WO2013047864A1 - Absorbent article

Info

Publication number: WO2013047864A1
Application number: PCT/JP2012/075287
Authority: WO
Inventors: Takashi Onozuka; Takashi Nomoto; Tomoyuki Saga; Noritomo Kameda; Yuki Noda; Tatsuya Tamura; Akira Hashino
Original assignee: Unicharm Corporation
Priority date: 2011-09-30
Filing date: 2012-09-25
Publication date: 2013-04-04
Also published as: TWI579005B; JP6041473B2; TW201328733A; AR088031A1; JP2013078375A

Abstract

Anabsorbent article includes an absorbent body having through-holes running from the skin facing side to the non-skin facing side. A top sheet at least partially covers the interior walls of the through-holes of the absorbent body, and the top sheet at least partially covering the interior walls of the through-holes is coated with a blood modifying agent. The blood modifying agent has an Inorganic-Organic Balance of 0.00-0.60, a melting point of no higher than 45 degree and a water solubility of no greater than 0.05 g in 100 g of water at 25 degree.

Description

DESCRIPTION

[TITLE OF THE INVENTION] Absorbent Article

Technical Field

[0001]

The present disclosure relates to an absorbent article.

Background Art

[0002]

PTL 1 discloses, for example, absorbent articles that have needle-like protrusions or conical protrusions applied to an absorbent body, whereby there are formed in the absorbent body through-holes passing through to the back side of the absorbent body, or blind holes that are depressions having depths of at least 50% of the

thickness of the absorbent body. Such a structure softens the absorbent body.

[Citation List]

[Patent Literature]

[0003] -

[PTL 1] Japanese Patent No. 3556581

[0004]

With the absorbent article described in PTL 1, however, the inventor has recognized that the absorbent body is not present directly under the sections of the top sheet that are above the through-holes or blind holes of the absorbent body, and therefore when menstrual blood of the wearer adheres to the top sheet, the menstrual blood adhering to those sections often remains without being absorbed into the absorbent body. Also, in an absorbent body obtained by covering a mixture of pulp and an absorbent polymer (SAP) with a tissue, the tissue tears when the through-holes or blind holes are formed in the absorbent body, and therefore the pulp and/or

absorbent polymer of the absorbent body often leaks through the through-holes or blind holes of the absorbent body. Summary

[0005]

Some embodiments of the invention provide an

absorbent article comprising a liquid-permeable top sheet provided on the skin facing side, a liquid-impermeable back sheet provided on the non-skin facing side, and a liquid-retaining absorbent body situated between the top sheet and back sheet and having through-holes running from the skin facing side to the non-skin facing side. The top sheet at least partially covers the interior walls of the through-holes of the absorbent body and the top sheet at least partially covering the interior walls of the through-holes is coated with a blood modifying agent. The blood modifying agent has an Inorganic- Organic Balance (IOB) of 0.00-0.60, a melting point of no higher than 45°C and a water solubility of no greater than 0.05 g in 100 g of water at 25°C.

Brief Description of Drawings

[0006]

Fig. 1 is a partial cutaway plan view of an

absorbent article according to at least one embodiment of the invention.

Fig. 2(a) is a schematic cross-sectional view showing a cross-section of the absorbent article of Fig. 1 along line A-A, and Fig. 2(b) is a schematic cross- sectional view of a through-hole of an absorbent article according to at least one embodiment of the invention.

Fig. 3 is a plan view of the absorbent body of an absorbent article according to at least one embodiment of the invention.

Fig. 4 is a diagram illustrating an example of a method of forming through-holes in a top sheet and absorbent body.

Fig. 5(a) is a schematic cross-sectional view of a modified example of an absorbent article according to at least one embodiment of the invention, and Fig. 5(b) is a schematic cross-sectional view of a through-hole of the modified example.

Fig. 6 is an electron micrograph of the skin contact surface of a top sheet in a sanitary napkin wherein the top sheet comprises tri-C2L oil fatty acid glycerides.

Fig. 7 is a pair of photomicrographs of menstrual blood containing and not containing a blood modifying agent .

Fig. 8 is a diagram illustrating a method of measuring surface tension.

DESCRIPTION OF EMBODIMENTS

[0007]

An absorbent article according to at least one embodiment of the invention will now be explained with reference to the accompanying drawings. However, the invention is not limited to the examples depicted in the drawings .

[0008]

Fig. 1 is partial cutaway plan view showing at least one embodiment of an absorbent article of the invention, and Fig. 2 is a schematic cross-sectional view showing a cross-section of the absorbent article of Fig. 1 along line A-A. The absorbent article 1 comprises a liquid- permeable top sheet 2 provided on the skin facing side, a liquid-impermeable back sheet 3 provided on the non-skin facing side, and a liquid-retaining absorbent body 4 situated between the top sheet 2 and the back sheet 3. The absorbent body 4 has through-holes 10 running from the skin facing side to the non-skin facing side of the absorbent body 4. The top sheet 2 covers interior walls of the through-holes of the absorbent body 4. The top sheet 2 also has a blood modifying agent-coated region 8 coated with a blood modifying agent on the areas where the through-holes 10 are formed.

[0009]

In the embodiment illustrated in Figs. 1 and 2, the absorbent article 1 further comprises a pair of side sheets 5 provided on both sides in the widthwise direction of the top sheet 2, and has a body section 6 and a pair of wing sections 7 extending from the body section 6 in the widthwise direction.

[0010]

The top sheet 2 and back sheet 3 are bonded at a seal section 11, for example by embossing. The back sheet 3 and side sheet 5 are also bonded at a seal section 12, for example by embossing. The seal sections 11,12 are provided on the outer periphery of the

absorbent article 1. In this embodiment, attachment parts 13,14 are provided on the non-skin facing side of the back sheet 3. In Fig. 1, the widthwise direction of the absorbent article 1 is the X-direction, and the lengthwise direction is the Y-direction. The planar direction is the direction of the plane defined by the X- and Y-directions .

[0011]

The shape of the body section 6 is not particularly restricted so long as it is a shape suited to the female body and the shape of shorts, such as roughly

rectangular, roughly elliptical or roughly hourglass- shaped. The dimensions in the lengthwise direction of the outer shape of the body section 6 are preferably 100- 500 mm and more preferably 150-350 mm. Also, the

dimensions in the widthwise direction of the outer shape of the body section 6 are preferably 30-200 mm and more preferably 40-180 mm.

[0012]

The top sheet 2 passes menstrual blood that has been excreted from the wearer into the absorbent body 4 provided under it. The top sheet 2 holds the absorbent body 4 in a manner with the absorbent body 4 held between it and the back sheet 3. All or a portion of the top sheet 2 is liquid-permeable, and the liquid-permeable areas of the top sheet 2 may be formed, for example, of a liquid-permeable nonwoven fabric or woven fabric, a resin film with a plurality of liquid-permeable holes formed therein, or a net-like sheet with a plurality of mesh holes .

[0013]

The material used for the nonwoven fabric or woven fabric in the top sheet 2 may be either natural fibers or chemical fibers. Examples of natural fibers include cellulose such as ground pulp and cotton. Examples of chemical fibers include regenerated cellulose such as rayon and fibril rayon, semi-synthetic cellulose such as acetate and triacetate, thermoplastic hydrophobic

chemical fibers, and hydrophilicized thermoplastic hydrophobic chemical fibers. Thermoplastic hydrophobic chemical fibers include monofilaments of polyethylene (PE) , polypropylene (PP) and polyethylene terephthalate (PET) , fibers obtained by graft polymerization of PE and PP, and composite fibers with a core-sheath structure or the like.

[0014]

Fabrication of a nonwoven fabric to be used in the top sheet 2 may be accomplished for example by web forming, with either a dry method (carding method, spunbond method, meltblown method or airlaid method) or wet method, or with a combination of a dry method and a wet method. The web bonding method for fabrication of a nonwoven fabric to be used in the top sheet 2 may be thermal bonding, needle punching, chemical bonding or the like, with no particular restriction to these methods. Spunlace formed into a sheet by a hydroentangling method may also be used in the top sheet 2. There may also be used for the top sheet 2 a nonwoven fabric having

irregularities on the skin facing side, such as a

nonwoven fabric having heat-shrinkable fibers or the like for shrinking on the lower layer side to form

irregularities on the upper layer side, or a nonwoven fabric in which irregularities are formed by applying air during web formation. Forming irregularities on the skin facing side in this manner can reduce the contact area between the top sheet 2 and the skin.

[0015]

As fibers in the nonwoven fabric for the top sheet 2 there may be used, for example, core-sheath type fibers wherein the melting point of the core component is higher than that of the sheath component, eccentric core-sheath type fibers, or side-by-side type composite fibers wherein the melting points of the left and right

components differ. In addition, hollow type fibers or flat fibers, or shaped fibers such as Y-shaped fibers or

C-shaped fibers, solid crimped fibers such as latent crimped or developed crimped fibers, or split fibers that have been split by a physical load such as a water stream, heat or embossing, may be combined in a nonwoven fabric to be used for the top sheet 2.

[0016]

In consideration of uptake of fluids and feel on the skin, the size of the fibers of a nonwoven fabric for use in the top sheet 2 is preferably 1.1-8.8 dtex.

[0017]

When hydrophobic synthetic fibers are used in the top sheet 2, in consideration of uptake of fluids and rewet backing by the top sheet 2, the hydrophobic

synthetic fibers may be mixed with a hydrophilic agent, water-repellent agent or the like, or the hydrophobic synthetic fibers may be coated with a hydrophilic agent, water-repellent agent or the like. The hydrophobic synthetic fibers may also be imparted with hydrophilicity by corona treatment or plasma treatment. This will allow the hydrophilic areas and lipophilic areas to be mutually isolated in the blood modifying agent-coated region 8 when the blood modifying agent is lipophilic, and both the hydrophilic components (mainly plasma) and lipophilic components (mainly blood cells) in menstrual blood will rapidly migrate from the top sheet 2 into the absorbent body 4.

[0018] In order to increase the concealing property of the top sheet 2, an inorganic filler such as titanium oxide, barium sulfate or calcium carbonate may be added to the fibers of the nonwoven fabric used in the top sheet 2. When the nonwoven fabric fibers are core-sheath type composite fibers, the inorganic filler may be added only to the core or only to the sheath.

[0019]

When a resin film or net-like sheet is to be used as the top sheet 2, the resin film or net-like sheet can be formed from polypropylene (PP) , polyethylene (PE) , polyethylene terephthalate (PET), or the like.

[0020]

As mentioned above, the top sheet 2 has a blood modifying agent-coated region 8 coated with a blood modifying agent. The blood modifying agent will now be described in detail. As explained hereunder, the

viscosity and surface tension of menstrual blood are lowered by the blood modifying agent of the blood

modifying agent-coated region 8, and menstrual blood that has been excreted into the blood modifying agent-coated region 8 of the top sheet 2 rapidly migrates from the top sheet 2 to the absorbent body 4 and is absorbed into the absorbent body 4. Since the absorption rate of menstrual blood absorbed into the absorbent body 4 is therefore high, highly viscous menstrual blood does not easily remain on the top sheet 2, and the top sheet 2 has a smooth feel without stickiness. Furthermore, since the viscosity and surface tension of highly viscous menstrual blood is lowered by the blood modifying agent and

menstrual blood therefore migrates to the absorbent body 4, masses of highly viscous menstrual blood do not easily remain on the top sheet and the wearer is less easily left with a visually unpleasant image. In addition, it is possible to inhibit sideway leakage of menstrual blood that has been excreted by the wearer onto the top sheet 2. [0021]

The coating basis weight of the blood modifying agent on the top sheet 2 is preferably 1-30 g/m² and more preferably 3-10 g/m². If the coating basis weight of the blood modifying agent is smaller than 1 g/m², it may be difficult to coat the blood modifying agent on the top sheet 2 in a stable manner, and if the coating basis weight of the blood modifying agent is greater than 30 g/m², the top sheet 2 may become greasy.

[0022]

After the blood modifying agent has been heated to a prescribed temperature, it is coated onto the top sheet 2 using a contact coater such as a slot coater, or a non- contact coater such as a spray coater, curtain coater or spiral coater. From the viewpoint of allowing uniform dispersion of the blood modifying agent in droplet form in the blood modifying agent-coated region 8, and

avoiding damage to the top sheet 2, it is preferred to coat the blood modifying agent on the top sheet 2 using a non-contact coater.

[0023]

When a nonwoven fabric is to be made for the top sheet, the nonwoven fabric may also be coated with a blood modifying agent. The top sheet 2 may also be coated with the blood modifying agent in the step of producing the absorbent article 1. However, the blood modifying agent is preferably coated on the top sheet 2 in the step of producing the absorbent article 1, since this can minimize equipment investment. Also, in order to prevent reduction in the amount of blood modifying agent coated on the top sheet 2 during the step of producing the absorbent article 1, it is preferred to coat the blood modifying agent on the top sheet 2 in a step near completion of the absorbent article 1. For example, the top sheet 2 may be coated with the blood modifying agent just before the step of wrapping the absorbent article 1. [0024]

The back sheet 3 prevents menstrual blood that has been absorbed into the absorbent body 4 from leaking to the outside. As the back sheet there may be used a liquid-impermeable film including polyethylene (PE) and polypropylene (PP) , an air-permeable resin film, a composite film comprising an air-permeable resin film bonded to a spunbond or spunlace nonwoven fabric, or an spunbond-meltblown-spunbond (SMS) nonwoven fabric

comprising a highly water-resistant meltblown nonwoven fabric sandwiched between high-strength spunbond nonwoven fabrics. In order to soften the absorbent article 1 so as not to impair the feel during wearing of the absorbent article 1A, it is preferred to use a resin film with a basis weight of 15-30 g/m², composed mainly of a low- density polyethylene (LDPE) resin, for example, as the back sheet 3.

[0025]

The absorbent body 4 has the function of absorbing and retaining menstrual blood. The absorbent body 4 preferably has high bulk, is resistant to deformation and has low chemical irritation. The absorbent body 4 used may be, for example, an absorbent body in which the structural materials of the absorbent body 4 such as hydrophilic fibers and an absorbent polymer (SAP) are covered with a covering material, or an absorbent body composed of structural materials of the absorbent body 4 such as fluffy pulp and an airlaid nonwoven fabric, and structural materials of the absorbent body 4 such as a super-absorbent polymer.

[0026]

Hydrophilic fibers for an absorbent body 4

comprising hydrophilic fibers or an absorbent polymer covered with a covering material include cellulose such as ground pulp and cotton, regenerated cellulose such as rayon or fibril rayon, semi-synthetic cellulose such as acetate and triacetate, particulate polymers, filamentous polymers, thermoplastic hydrophobic chemical fibers, hydrophilicized thermoplastic hydrophobic chemical fibers, and mixtures of the foregoing materials.

Cellulose foam and synthetic resin continuous foam may also be used in the absorbent body 4. Also, a foam or sheeted material may be pulverized and then molded into the absorbent body shape for use as the absorbent body 4. Preferably, ground pulp is used as the hydrophilic fibers for the absorbent body 4, in consideration of reducing cost and facilitating molding.

[0027]

As super-absorbent polymers for such an absorbent body 4 there are commonly used particulate polymers such as sodium acrylate copolymer which exhibits absorptivity and hygroscopicity. In order to impart other functions to the polymer, silver, copper, zinc, silica, active carbon, an aluminosilicate compound, zeolite or the like may also be added to the polymer. This can impart functions such as deodorant, antibacterial or heat- absorbing effects to the polymer.

[0028]

The covering material in an absorbent body 4, wherein the structural material of the absorbent body 4 such as hydrophilic fibers or an absorbent polymer is covered with a covering material, is not particularly restricted so long as it has liguid-permeability and a barrier property so that the polymer absorbent body does not slip. For example, a woven fabric or nonwoven fabric may be used as the covering material. The material of the woven fabric or nonwoven fabric may be either natural fibers or chemical fibers. Examples of natural fibers include cellulose such as ground pulp and cotton.

Chemical fibers include regenerated cellulose such as rayon and fibril rayon, semi-synthetic cellulose such as acetate and triacetate, thermoplastic hydrophobic

chemical fibers, and hydrophilicized thermoplastic hydrophobic chemical fibers. [0029]

Web forming for fabrication of a nonwoven fabric to be used in a covering material may be accomplished by either a dry method (carding method, spunbond method, meltblown method or airlaid method) or wet method, or a combination of a dry method and a wet method. The method of bonding the nonwoven fabric to be used in a covering material may be thermal bonding, needle punching, chemical bonding or the like, with no particular

restriction to these methods. Spunlace formed into a sheet by a hydroentangling method may also be used in the covering material. The covering material is preferably tissue composed mainly of ground pulp and formed by a wet method, in consideration of reducing cost and increasing the barrier property.

[0030]

An absorbent sheet and polymer sheet may be used in the absorbent body 4. This can result in a thinner absorbent body 4. In this case, the thickness of the absorbent body 4 is preferably 0.3-5 mm. Absorbent sheets include pulp sheets prepared as sheets from a structural materials such as fibers using a binder or the like. Polymer sheets include composite sheets obtained by forming sheets of a structural material such as ground pulp or fiber mixed with structural material such as a particulate polymer. A sheet formed by mixing a

particulate polymer with fibers may be a sheet of a particulate polymer dispersed in a laminar form in the fibers, or a sheet in which the particulate polymer is dispersed in the fibers in a three-dimensional manner.

[0031]

The fibers to be used in an absorbent sheet or polymer sheet are preferably cellulose fibers such as wood pulp, regenerated cellulose fibers such as rayon or cupra, hydrophilic synthetic fibers such as polyvinyl alcohol fibers or polyacrylonitrile fibers, or fibers of polyethylene, polypropylene, polyethylene terephthalate, polyethylene/polypropylene composite fibers or

polyethylene/polyethylene terephthalate composite fibers, where the fibers surfaces have been hydrophilicized with a surfactant or the like. From the viewpoint of

satisfactorily maintaining hydrophilicity of the fibers, the fibers to be used in an absorbent sheet or polymer sheet are preferably cellulose fibers. A particulate polymer to be used in a polymer sheet is preferably a polymer that can absorb and retain over 20 times its own weight in fluid, and that can gel. Such polymers include starch, crosslinked carboxymethylated cellulose,

polyacrylic acid and its salts, and polyacrylate graft polymers .

[0032]

As mentioned above, the absorbent body 4 has

through-holes 10 running from the skin facing side to the non-skin facing side of the absorbent body 4. This will allow the absorbent body 4 to absorb menstrual blood excreted by the wearer not only on the skin facing side and non-skin facing side of the absorbent body 4, but also at the interior walls of the through-holes 10, thereby allowing more rapid absorption of menstrual blood by the absorbent body 4. In addition, since the

absorbent body 4 can absorb menstrual blood at sections near the back sheet 3 in the interior walls of the through-holes 10, the absorbent body 4 is able to absorb menstrual blood at sections of the absorbent body 4 away from the skin of the wearer. This allows the wearer to comfortably wear the absorbent article even after

menstrual blood has been excreted into the absorbent article 1. In addition, the air permeability of the absorbent article 1 is satisfactory due to the through- holes 10 provided in the absorbent body 4.

[0033]

The number of through-holes 10 per 1 cm² on the skin facing side of the absorbent body 4 is preferably 1-10 and more preferably 1-5. If the number of through-holes 10 per 1 cm² on the skin facing side of the absorbent body 4 is less than 1, the aforementioned effect of more rapid absorption of menstrual blood by the through-holes 10 may not be obtained. Also, if the number of through-holes 10 per 1 cm² on the skin facing side of the absorbent body 4 is greater than 10, menstrual blood absorbed by the absorbent body 4 will not spread very much in the planar direction, and it may not be possible to absorb menstrual blood in a wide area on the skin facing side of the absorbent body 4. Also, if the number of through-holes

10 per 1 cm² on the skin facing side of the absorbent body 4 is greater than 10, the amount of absorbed menstrual blood that can be absorbed by the absorbent body 4 may be reduced.

[0034]

The open area of each of the through-holes 10 is preferably 0.01-10 mm² and more preferably 0.1-2.5 mm². If the open area of each of the through-holes 10 is smaller than 0.01 mm², menstrual blood may not penetrate to the interior walls of the through-holes 10. Also, if the open area of each of the through-holes 10 is greater than 10 mm², the aforementioned effect of more rapid absorption of menstrual blood by the through-holes 10 may not be obtained. For example, the open area of the through-hole is measured on the skin facing side of top sheet .

[0035]

As shown in Fig. 3, the absorbent body 4 has an absorbent body core region 41 in which the through-holes 10 are formed, and an absorbent body peripheral region 42 surrounding the absorbent body core region 40. The thickness of the absorbent body 4 does not need to be consistent throughout the entire absorbent body 4, and for example, the thickness of the absorbent body 4 in the absorbent body core region 41 may differ from the

thickness of the absorbent body 4 in the absorbent body peripheral region 42. For example, the thickness of the absorbent body 4 in the absorbent body core region 41 may be greater than the thickness of the absorbent body 4 in the absorbent body peripheral region 42. This can facilitate adhesion of the absorbent article 1 to the skin of the wearer. For example, the thickness of the absorbent body 4 in the absorbent body core region 41 may be 2 mm and the thickness of the absorbent body 4 in the absorbent body peripheral region 42 may be 1 mm.

[0036]

The basis weight of the absorbent body 4 also does not need to be consistent throughout the entire absorbent body 4, and for example, the basis weight of the

absorbent body 4 in the absorbent body core region 41 may differ from the basis weight of the absorbent body 4 in the absorbent body peripheral region 42. For example, the basis weight of the absorbent body 4 in the absorbent body core region 41 may be higher than the basis weight of the absorbent body 4 in the absorbent body peripheral region 42. This will cause menstrual blood absorbed into the absorbent body 4 to be concentrated in the absorbent body core region 41. When the structural materials of the absorbent body 4 are pulp and an absorbent polymer (SAP) , for example, the basis weight of the pulp of the absorbent body 4 may be 300 g/m² and the basis weight of the absorbent polymer may be 30 g/m² in the absorbent body core region 41, while the basis weight of the pulp of the absorbent body 4 may be 100 g/m² and the basis weight of the absorbent polymer may be 10 g/m² in the absorbent body peripheral region 42.

[0037]

As mentioned above, the interior walls of the through-holes 10 of the absorbent body 4 are covered by the top sheet 2. This can minimize leakage of the structural materials of the absorbent body 4 from the through-holes 10 of the absorbent body 4. So long as the top sheet 2 covers the interior walls of the through- holes 10 to an extent allowing leakage of the structural materials of the absorbent body 4 from the through-holes 10 of the absorbent body 4 to be minimized, the top sheet 2 does not need to completely cover the interior walls of the through-holes 10.

[0038]

Since the top sheet 2 covers the interior walls of the through-holes 10, the absorbent body is not present directly below the areas of the top sheet 2 above the through-holes 10 of the absorbent body 4. Consequently, residue of menstrual blood on the top sheet 2 can be reduced.

[0039]

By covering the interior walls of the through-holes by the top sheet 2, menstrual blood permeating into the through-holes rapidly spreads through the top sheet 2 throughout the entirety of the interior walls, and can be rapidly absorbed into the absorbent body 2. By covering the interior walls of the through-holes with the top sheet 2, the absorbent body 2 can also rapidly absorb highly viscous menstrual blood.

[0040]

Lower friction between the skin of the wearer and the top sheet 2 will reduce stress on the wearer caused by the absorbent article 1. The areas of the top sheet 2 covering the interior walls of the through-holes do not contact the skin of the wearer, and do not cause friction with the skin of the wearer. Consequently, covering the interior walls of the through-holes by the top sheet 2 can reduce stress on the wearer caused by the absorbent article 1.

[0041]

A method of forming through-holes 10 in the

absorbent body 4, whose interior walls are covered by the top sheet 2, will now be explained. Fig. 4 is a diagram illustrating an example of a method of forming through- holes 10 in the top sheet 2 and absorbent body 4.

[0042] A top sheet 122 fed from a top sheet roll 120 is placed above a belt conveyor 110.

[0043]

Ground pulp and an absorbent polymer 132 are supplied from a ground pulp/absorbent polymer supply apparatus (not shown), to a pattern drum 130. Recesses 134 are formed around the outer periphery of the pattern drum 130, as a mold into which the mixture of the ground pulp and the absorbent polymer is filled. The interior of the pattern drum 130 is aspirated 136, and the ground pulp 132 supplied to the pattern drum 130 is drawn into the recesses 134 and compressed. The absorbent body 112 molded in the recesses 134 is then placed on the top sheet 122.

[0044]

Next, a through-hole forming apparatus 140 is used to form through-holes in the top sheet 122 and absorbent body 112, running through them in the thickness

direction. The through-hole forming apparatus 140 comprises a protrusion roll 141 having a plurality of needle-like, circular cylindrical or conical shaped protrusions 141a on the outer peripheral surface, and an anvil roll 142 having recesses 142a on the outer

peripheral surface which engages with the protrusions 141a, at locations corresponding to the protrusions 141a of the protrusion roll 141.

[0045]

As the protrusions 141a of the protrusion roll 141 penetrate the top sheet 122 on which the absorbent body 112 has been laminated, through-holes are formed in the top sheet 122 and absorbent body 112. The rotational speeds of the protrusion roll 141 and anvil roll 142 are adjusted so that holes are opened in the top sheet 122 after the top sheet 122 has been stretched. This allows through-holes having their interior walls covered by the top sheet 122 to be formed in the absorbent body 112.

[0046] As mentioned above, the top sheet 2 has a blood modifying agent-coated region 8 coated with a blood modifying agent formed on the regions where the through- holes 10 have been formed. Thus, the blood modifying agent is coated not only on the top sheet 2 situated on the skin facing side of the absorbent body 4, but also on the top sheet 2 covering the interior walls of the through-holes 10. As explained hereunder, the viscosity and surface tension of menstrual blood excreted into the blood modifying agent-coated region 8 are lowered by the blood modifying agent of the blood modifying agent-coated region 8, and menstrual blood that has been excreted into the blood modifying agent-coated region 8 of the top sheet 2 rapidly migrates from the top sheet 2 to the absorbent body 4 and is absorbed into the absorbent body

4. Therefore, coating the blood modifying agent on the top sheet 2 that covers the interior of the through-holes 10 allows menstrual blood penetrating the through-holes 10 to rapidly migrate from the top sheet 2 to the

absorbent body 4, and to be rapidly absorbed into the absorbent body 4. In addition, since the blood modifying agent lowers the viscosity and surface tension of highly viscous menstrual blood and causes the menstrual blood to migrate into the absorbent body 4, masses of highly viscous menstrual blood do not easily remain in the interior of the through-holes 10, and it is possible to help prevent the through-holes 10 from being blocked by masses of highly viscous menstrual blood.

[0047]

Incidentally, the blood modifying agent may be coated onto all of the through-holes 10 formed in the absorbent article 1, or the blood modifying agent may be coated only onto some of the through-holes 10 formed in the absorbent article 1.

[0048]

The side sheet 5 shown in Fig. 1 and Fig. 2 prevents menstrual blood from leaking through the top sheet 2 to the outside of the absorbent article 1 in the widthwise direction. The side sheet 5 preferably has

hydrophobicity and water-repellency . A spunbond nonwoven fabric or SMS nonwoven fabric, for example, is used for the side sheet 5. In addition, since the side sheet 5 contacts with the skin of the wearer, an air-through nonwoven fabric that can reduce rubbing irritation on the skin is preferably used as the side sheet 5. The side sheet 5 is not necessary in the absorbent article 1.

[0049]

The top sheet 2, back sheet 3, absorbent body 4 and side sheet 5 are preferably bonded together to prevent interlayer separation between them. Their bonding may be accomplished, for example, by embossing, ultrasonic waves, with a hot-melt adhesive, or by a combination of the foregoing techniques. The top sheet 2 and back sheet 3 are bonded at a seal section 11 by embossing. The back sheet 3 and side sheet 5 are also bonded at a seal section 12 by embossing. The top sheet 2 and side sheet 5 are bonded by a hot-melt adhesive on both sides of the body section 6.

[0050]

As an example of embossing, the top sheet and back sheet, or the top sheet and back sheet and side sheet, may be passed together between a patterned embossing roll and a flat roll, and the perimeter of the absorbent body embossed (a method known as round sealing) . This will form seal sections 11,12 in the absorbent article 1. By heating the embossing roll and/or flat roll, each sheet is softened so that the seal sections 11,12 become more distinct. Emboss patterns include lattice-like patterns, zigzag patterns and wavy patterns. In order to inhibit bending of the absorbent article 1 at the borders of the seal sections 11,12, the emboss pattern is preferably intermittently elongated.

[0051]

When a hot-melt adhesive is used to bond the top sheet, back sheet, absorbent body and side sheet, a hot- melt adhesive is coated onto each sheet by a coating method such as spiral coating, coater coating, curtain coater coating or Summit gun coating. The sheets are then stacked and bonded together. After the sheets have been bonded together, they may be subjected to embossing to increase the peel strength between the sheets.

[0052]

Hot-melt adhesives to be used for bonding the sheets together include pressure-sensitive adhesives and heat- sensitive adhesives composed mainly of rubber-based compounds such as styrene-ethylene-butadiene-styrene (SEBS) , styrene-butadiene-styrene (SBS) or styrene- isoprene-styrene (SIS) , or composed mainly of olefin- based compounds such as linear low-density polyethylene, and water-sensitive adhesives such as polyvinyl alcohol, carboxylmethylcellulose and gelatin comprising water- soluble polymers or polyvinyl acetate and sodium

polyacrylate comprising water-swelling polymers. When the adhesive seeps out to the exterior, a heat-sensitive adhesive with tack is preferably used as the hot-melt adhesive for bonding between the sheets. Specific examples include adhesives prepared by melt mixing of 5- 25% of SEBS, 40-60% of an alicyclic saturated

hydrocarbon, 1-10% of an aromatic-modified terpene and

15-35% of an additive.

[0053]

The wing sections 7 if provided in the absorbent article 1 stably anchor the absorbent article 1 to underwear. After the wing sections 7 have been folded on the outer side of the underwear, the absorbent article is attached to the crotch section of the underwear by the attachment part 13 to allow the absorbent article 1 to be stably anchored to the underwear. The shapes of the wing sections 7 are roughly rectangular.

[0054]

The attachment part 14 on the non-skin facing side of the back sheet 3 anchors the body section 6 to the inside of the crotch section of the underwear, and the attachment part 13 on the non-skin facing side of the wing sections 7 anchors the wing sections 7 to the outside of the crotch section of the underwear. The pressure-sensitive adhesive used to form the attachment parts 13,14 is preferably, for example, one composed mainly of a styrene-based polymer, tackifier or

plasticizer. Styrene-based polymers include styrene- ethylene-butylene-styrene block copolymer, styrene- butylene polymer, styrene-butylene-styrene block

copolymer and styrene-isobutylene-styrene copolymer, any of which may be used alone or as polymer blends of 2 or more. Styrene-ethylene-butylene-styrene block copolymer is preferred as the pressure-sensitive adhesive for the attachment parts 13,14 from the viewpoint of satisfactory thermostability.

[0055]

An organic compound that is solid at ordinary temperature is preferably used as the tackifier and plasticizer. A tackifier may be, for example, a C5 petroleum resin, C9 petroleum resin, dicyclopentadiene- based petroleum resin, rosin-based petroleum resin, polyterpene resin, terpenephenol resin or the like, and a plasticizer may be, for example, a monomer plasticizer such as tricresyl phosphate, dibutyl phthalate or dioctyl phthalate, or a polymer plasticizer such as a vinyl polymer or polyester.

[0056]

The blood modifying agent to be coated onto the blood modifying agent-coated region 8 will now be

explained in detail. The blood modifying agent lowers the viscosity and surface tension of menstrual blood after highly viscous menstrual blood has been absorbed by the top sheet 2, and allows menstrual blood to rapidly migrate from the top sheet 2 into the absorbent body 4. Thus, highly viscous menstrual blood does not easily remain on the top sheet 2, and the top sheet 2 has a smooth feel without stickiness. Furthermore, since the viscosity and surface tension of highly viscous menstrual blood is lowered by the blood modifying agent and

menstrual blood therefore migrates to the absorbent body 4, masses of highly viscous menstrual blood do not easily remain on the top sheet and the wearer is less easily left with a visually unpleasant image.

[Blood modifying agent]

The blood modifying agent of this disclosure has an

IOB of about 0 to about 0.60, a melting point of no higher than about 45°C, and a water solubility of no greater than about 0.05 g in lOOg water at 25°C.

[0057]

The IOB (Inorganic Organic Balance) is an indicator of the hydrophilic-lipophilic balance, and as used herein, it is the value calculated by the following formula by Oda et al . :

IOB = inorganic value/organic value.

[0058]

The inorganic value and the organic value are based on the organic paradigm described in "Organic compound predictions and organic paradigms" by Fujita A., Kagaku no Ryoiki (Journal of Japanese Chemistry), Vol.11, No.10 (1957) p.719-725 which is incorporated by reference herein .

The organic values and inorganic values of major groups, according to Fujita, are summarized in Table 1 below.

[0059] Table 1

[0060]

For example, in the case of an ester of

tetradecanoic acid which has 14 carbon atoms and dodecyl alcohol which has 12 carbon atoms, the organic value is 520 (CH₂, 20 x 26) and the inorganic value is 60 (-COOR, 60 x 1), and therefore IOB = 0.12.

[0061]

In the blood modifying agent, the IOB is about 0.00-

0.60, preferably about 0.00-0.50, more preferably about 0.00-0.40 and even more preferably about 0.00-0.30. This is because a lower IOB is associated with higher

organicity and higher affinity with blood cells.

[0062]

As used herein, the term "melting point" refers to the peak top temperature for the endothermic peak during conversion from solid to liguid, upon measurement with a differential scanning calorimetry analyzer at a

temperature-elevating rate of 10°C/min. The melting point may be measured using a Model DSC-60 DSC measuring apparatus by Shimadzu Corp., for example.

[0063] If the blood modifying agent has a melting point of no higher than about 45°C, it may be either liquid or solid at room temperature, or in other words, the melting point may be either about 25°C or higher or below about 25°C, and for example, it may have a melting point of about -5°C or about -20°C. The reason for a melting point of no higher than about 45°C for the blood modifying agent will be explained below.

[0064]

The blood modifying agent does not have a lower limit for the melting point, but the vapor pressure is preferably low. The vapor pressure of the blood

modifying agent is preferably about 0.00-0.01 Pa, more preferably about 0.000-0.001 Pa and even more preferably about 0.0000-0.0001 Pa, at 1 atmosphere, 25°C.

Considering that the absorbent article of this disclosure is to be used in contact with the human body, the vapor pressure is preferably about 0.00-0.01 Pa, more

preferably about 0.000-0.001 Pa and even more preferably about 0.0000-0.0001 Pa, at 1 atmosphere, 40°C. If the vapor pressure is high, gasification may occur during storage and the amount of blood modifying agent may be reduced, and may create problems such as odor during wear .

[0065]

The melting point of the blood modifying agent may also differ depending on the weather or duration of wear. For example, in regions with a mean atmospheric

temperature of no higher than about 10°C, using a blood modifying agent with a melting point of no higher than about 10°C may allow the blood modifying agent to stably modify blood after excretion of menstrual blood, even if it has been cooled by the ambient temperature.

Also, when the absorbent article is used for a prolonged period of time, the melting point of the blood modifying agent is preferably at the high end of the range of no higher than about 45°C. This is because the blood modifying agent is not easily affected by sweat or friction during wearing, and will not easily migrate even during prolonged wearing.

[0066]

The water solubility of 0.00-0.05 g may be measured by adding 0.05 g of sample to 100 g of deionized water at 25°C, allowing it to stand for 24 hours, and after 24 hours, gently stirring if necessary, and then visually evaluating whether or not the sample has dissolved.

As used herein, the term "solubility" in regard to water solubility includes cases where the sample

completely dissolves in deionized water to form a

homogeneous mixture, and cases where the sample is completely emulsified. As used herein, "completely" means that no mass of the sample remains in the deionized water .

[0067]

When top sheet surfaces are coated with surfactants in order to alter the surface tension of blood and promote the rapid absorption of blood, because

surfactants generally have high water solubility, the surfactant-coated top sheet is highly miscible with hydrophilic components (such as blood plasma) in the blood and therefore, instead, they tend to cause residue of blood on the top sheet. The aforementioned blood modifying agent has low water solubility and, therefore, it does not cause residue of blood on the top sheet and allows rapid migration into the absorbent body.

[0068]

As used herein, a water solubility of water at 25°C may be simply referred to as "water solubility".

[0069]

As used herein, "weight-average molecular weight" includes the concept of a polydisperse compound (for example, a compound produced by stepwise polymerization, an ester formed from a plurality of fatty acids and a plurality of aliphatic monohydric alcohols), and a simple compound (for example, an ester formed from one fatty acid and one aliphatic monohydric alcohol) , and in a system comprising Ni molecules with molecular weight i (i

= 1, or i = 1, 2 . . . ), it refers to M_w determined by the following formula.

[0070]

As used herein, the weight-average molecular weights are the values measured by gel permeation chromatography (GPC), based on polystyrene.

The GPC measuring conditions may be the following, for example.

Device: Lachrom Elite high-speed liguid chromatogram by Hitachi High-Technologies Corp.

Columns: SHODEX KF-801, KF-803 and KF-804, by Showa Denko K.K.

Eluent: THF

Flow rate: 1.0 mL/min

Driving volume: 100 μΐι

Detection: RI (differential refractoraeter )

The weight-average molecular weights listed in the examples of the present specification were measured under the conditions described below.

[0071]

Preferably, the blood modifying agents are selected from the group consisting of the following items (i)- (iii) , and any combination thereof:

(i) a hydrocarbon;

(ii) a compound having (ii-1) a hydrocarbon moiety, and (ii-2) one or more groups each selected from the group consisting of carbonyl group (-CO-) and oxy group (-0-) inserted between a C-C single bond of the

hydrocarbon moiety; and

(iii) a compound having (iii-1) a hydrocarbon moiety, (iii-2) one or more groups each selected from the group consisting of carbonyl group (-CO-) and oxy group (-0-) inserted between a C-C single bond of the

hydrocarbon moiety, and (iii-3) one or more groups each selected from the group consisting of carboxyl group (- COOH) and hydroxyl group (-OH) substituting a hydrogen of the hydrocarbon moiety.

[0072]

As used herein, "hydrocarbon" refers to a compound composed of carbon and hydrogen, and it may be a chain hydrocarbon, such as a paraffinic hydrocarbon (containing no double bond or triple bond, also referred to as alkane) , an olefin-based hydrocarbon (containing one double bond, also referred to as alkene) , an acetylene- based hydrocarbon (containing one triple bond, also referred to as alkyne) , or a hydrocarbon comprising two or more bonds each selected from the group consisting of double bonds and triple bonds, and cyclic hydrocarbon, such as aromatic hydrocarbons and alxcyclic hydrocarbons.

[0073]

Preferred as such hydrocarbons are chain

hydrocarbons and alicyclic hydrocarbons, with chain hydrocarbons being more preferred, paraffinic

hydrocarbons, olefin-based hydrocarbons and hydrocarbons with two or more double bonds (containing no triple bond) being more preferred, and paraffinic hydrocarbons being even more preferred.

Chain hydrocarbons include linear hydrocarbons and branched hydrocarbons.

[0074]

When two or more oxy group (-0-) are inserted in the compounds of (ii) and (iii) above, the oxy group (-0-) are not adjacent to each other. Thus, compounds (ii) and (iii) do not include compounds with continuous oxy group (i.e., peroxides).

[0075]

In the compounds of (iii) , compounds in which at least one hydrogen on the hydrocarbon moiety is substituted with a hydroxyl group (-OH) are more

preferred than compounds in. which at least one hydrogen on the hydrocarbon moiety is substituted with a carboxyl group (-COOH) . As shown in Table 1, the carboxyl groups bond with metals and the like in menstrual blood, drastically increasing the inorganic value from 150 to 400 or greater, and therefore a blood modifying agent with carboxyl groups can increase the IOB value to more than about 0.6 during use, potentially lowering the affinity with blood cells.

[0076]

More preferably, the blood modifying agent is a compound selected from the group consisting items (i')~ (iii'), and any combination thereof:

(i') a hydrocarbon;

(ii¹) a compound having at least (ii'-l) a

hydrocarbon moiety, and (ii'-2) one or more bonds each selected from the group consisting of carbonyl bond (-CO- ) , at least one ester bond (-COO-) , at least one

carbonate bond (-OCOO-) , and at least one ether bond (-0-

) inserted between a C-C single bond of the hydrocarbon moiety; and

(iii') a compound having at least one(iii'-l) a hydrocarbon moiety, (iii' -2) one or more bonds each selected from the group consisting of carbonyl bond (-CO-

), at least one ester bond (-COO-) , at least one

carbonate bond (-OCOO-) , and at least one ether bond (-0- ) inserted between a C-C single bond of a hydrocarbon and (iii' -3) one or more groups each selected from the group consisting of carboxyl group (-COOH) and hydroxyl group

(-OH) substituting a hydrogen on the hydrocarbon moiety.

[0077]

When 2 or more same or different bonds are inserted in the compound of (ϋ') or (iii¹), i.e., when 2 or more bonds each selected from the group consisting of carbonyl bonds (-CO-), ester bonds (-C00-) , carbonate bonds (- 0C00-) and ether bonds (-0-) are inserted, the bonds are not adjacent to each other, and at least one carbon atom lies between each of the bonds.

[0078]

The blood modifying agent is more preferably a compound with no more than about 1.8 carbonyl bonds (-CO-

), no more than 2 ester bonds (-COO-) , no more than about 1.5 carbonate bonds (-OCOO-) , no more than about 6 ether bonds (-0-) , no more than about 0.8 carboxyl groups (- COOH) and/or no more than about 1.2 hydroxyl groups (- OH) , per 10 carbon atoms in the hydrocarbon moiety.

[0079]

Even more preferably, the blood modifying agent is selected from the group consisting of the following items (A) -(F), and any combination thereof:

(A) an ester of (Al) a compound having a chain hydrocarbon moiety and 2-4 hydroxyl groups substituting hydrogens on the chain hydrocarbon moiety, and (A2) a compound having a chain hydrocarbon moiety and 1 carboxyl group substituting a hydrogen on the chain hydrocarbon moiety;

(B) an ether of (Bl) a compound having a chain hydrocarbon moiety and 2-4 hydroxyl groups substituting hydrogens on the chain hydrocarbon moiety and (B2) a compound having a chain hydrocarbon moiety and 1 hydroxyl group, substituting a hydrogen on the chain hydrocarbon moiety;

(C) an ester of (CI) a carboxylic acid, hydroxy acid, alkoxy acid or oxoacid comprising a chain

hydrocarbon moiety and 2-4 carboxyl groups substituting hydrogens on the chain hydrocarbon moiety and (C2) a compound having a chain hydrocarbon moiety and 1 hydroxyl group substituting a hydrogen on the chain hydrocarbon moiety;

(D) a compound having a chain hydrocarbon moiety and one bond selected from the group consisting of ether bond

(-0-), carbonyl bond (-CO-), ester bond (-C00-) and carbonate bond (-OCOO-) inserted in-between a C-C single bond of the chain hydrocarbon moiety;

(E) a polyoxy C₂- 6 alkylene glycol, or alkyl ester or alkyl ether thereof; and

(F) a chain hydrocarbon.

The blood modifying agent in accordance with (A) to

(F) will now be described in detail.

[0080]

[ (A) Ester of (Al) a compound having a chain hydrocarbon moiety and 2-4 hydroxyl groups substituting hydrogens on the chain hydrocarbon moiety, and (A2) a compound having a chain hydrocarbon moiety and 1 carboxyl group

substituting a hydrogen on the chain hydrocarbon moiety]

The (A) ester of (Al) a compound having a chain hydrocarbon moiety and 2-4 hydroxyl groups substituting hydrogens on the chain hydrocarbon moiety, and (A2) a compound having a chain hydrocarbon moiety and 1 carboxyl group substituting a hydrogen on the chain hydrocarbon moiety (hereunder also referred to as "compound (A)") includes esters of a compound with 4, 3 or 2 hydroxyl groups and a compound with 1 carboxyl group, and it is not necessary for all of the hydroxyl groups to be esterified so long as the IOB, melting point and water solubility are within the aforementioned ranges.

[0081]

Examples of (Al) a compound having a chain

hydrocarbon moiety and 2-4 hydroxyl groups substituting hydrogens on the chain hydrocarbon moiety (hereunder also referred to as "compound (Al)") include chain hydrocarbon tetraols such as alkanetetraols, including

pentaerythritol, chain hydrocarbon triols such as

alkanetriols, including glycerins, and chain hydrocarbon diols such as alkanediols, including glycols. Examples of (A2) a compound having a chain hydrocarbon moiety and 1 carboxyl group substituting a hydrogen on the chain hydrocarbon moiety (hereunder also referred to as

"compound (A2)") include compounds in which one hydrogen on the hydrocarbon is substituted with one carboxyl group (-COOH) , such as fatty acids.

Examples for compound (A) include (ai) an ester of a chain hydrocarbon tetraol and at least one fatty acid,

(a₂) an ester of a chain hydrocarbon triol and at least one fatty acid, and (a3) an ester of a chain hydrocarbon diol and at least one fatty acids.

[0082]

[ (ai) Ester of a chain hydrocarbon tetraol and at least one fatty acid]

Examples of an ester of a chain hydrocarbon tetraol and at least one fatty acid include tetraesters of pentaerythritol and fatty acids, represented by the following formula (1) :

triesters of pentaerythritol and fatty acids, represented by the following formula (2) :

diesters of pentaerythritol and fatty acids, represented by the following formula (3) :

and monoesters of pentaerythritol and fatty acids, represented by the following formula

In the formulae, R¹-R⁴ each represent a chain

hydrocarbon.

[0083]

The fatty acids composing the esters of

pentaerythritol and fatty acids (F^COOH, R²COOH, R³COOH, and R⁴COOH) are not particularly restricted as long as the pentaerythritol and fatty acid esters satisfy the

conditions for the IOB, melting point and water

solubility, and for example, there may be mentioned saturated fatty acids, such as C2-C30 saturated fatty acids, including acetic acid (C2) (C₂ representing the number of carbons, corresponding to the number of carbons of each of ^ , R²C, R³C or R C, same hereunder) , propanoic acid (C₃) , butanoic acid (C₄) and isomers thereof such as 2-methylpropanoic acid (C₄) , pentanoic acid (C₅) and isomers thereof such as 2-methylbutanoic acid (C₅) and

2 , 2-dimethylpropanoic acid (C₅) , hexanoic acid {Cs) , heptanoic acid (C₇) , octanoic acid (C₈) and isomers thereof, such as 2-ethylhexanoic acid (Cs) , nonanoic acid (Cg) , decanoic acid (C10) , dodecanoic acid (C₁₂) ,

tetradecanoic acid (C14) , hexadecanoic acid (Ci6) ,

heptadecanoic acid (C_i7) , octadecanoic acid (Cie) ,

eicosanoic acid (C₂o) , docosanoic acid (C₂₂) , tetracosanoic acid (C₂₄) , hexacosanoic acid (C₂6) , octacosanoic acid

(C₂₈) and triacontanoic acid (C₃₀) , as well as isomers of the foregoing (excluding those mentioned above) .

[0084]

The fatty acid may also be an unsaturated fatty acid. Examples of unsaturated fatty acids include C₃-C₂₀ unsaturated fatty acids, such as monounsaturated fatty acids including crotonic acid (C₄) , myristoleic acid (Ci₄) , palmitoleic acid (Ci₆) , oleic acid (Ci₈) , elaidic acid (Cie) , vaccenic acid (Ci₈) , gadoleic acid (C₂o) and eicosenoic acid (C₂o) , di-unsaturated fatty acids

including linolic acid (Ci₈) and eicosadienoic acid (C₂o) tri-unsaturated fatty acids including linolenic acids, such as ct-linolenic acid (Ci₈) and γ-linolenic acid (Ci₈) , pinolenic acid (Ci₈) , eleostearic acids, such as a- eleostearic acid (Ci₈) and β-eleostearic acid (Ci₈) , Mead acid (C₂o) , dihomo-y-linolenic acid (C₂o) and

eicosatrienoic acid (C₂₀) , tetra-unsaturated fatty acids including stearidonic acid (C₂o) , arachidonic acid (C₂o) and eicosatetraenoic acid (C₂₀) , penta-unsaturated fatty acids including bosseopentaenoic acid (Ci₈) and

eicosapentaenoic acid (C20) , and partial hydrogen adducts of the foregoing.

[0085]

Considering the potential for degradation by

oxidation and the like, the ester of pentaerythritol and a fatty acid is preferably an ester of pentaerythritol and a fatty acid, which is derived from a saturated fatty acid, i.e., an ester of pentaerythritol and a saturated fatty acid.

Also, in order to lower the IOB and result in greater hydrophobicity, the ester of pentaerythritol and a fatty acid is preferably a diester, triester or

tetraester, more preferably a triester or tetraester, and even more preferably a tetraester.

[0086]

In a tetraester of pentaerythritol and a fatty acid, the IOB is 0.60 if the total number of carbons of the fatty acid composing the tetraester of the

pentaerythritol and fatty acid, i.e., the total number of carbons of the F^C, R²C, R³C and R⁴C portions in formula

(1), is 15. Thus, when the total number of carbons of the fatty acid composing the tetraester of the

pentaerythritol and fatty acid is approximately 15 or greater, the IOB satisfies the condition of being within about 0.00 to 0.60.

Examples of tetraesters of pentaerythritol and fatty acids include tetraesters of pentaerythritol with

hexanoic acid {CQ) , heptanoic acid (C₇) , octanoic acid (Cs) such as 2-ethylhexanoic acid (C₈) , nonanoic acid (Cg) , decanoic acid (Cio) and/or dodecanoic acid (C12) .

[0087]

In a triester of pentaerythritol and a fatty acid, the IOB is 0.58 if the total number of carbons of the fatty acid composing the triester of the pentaerythritol and fatty acid, i.e., the total number of carbons of the ^C, R²C and R³C portions in formula (2), is 19. Thus, when the total number of carbons of the fatty acid composing the triester of the pentaerythritol and fatty acid is approximately 19 or greater, the IOB satisfies the condition of being within about 0.00 to 0.60.

[0088]

In a diester of pentaerythritol and a fatty acid, the IOB is 0.59 if the total number of carbons of the fatty acid composing the diester of the pentaerythritol and fatty acid, i.e., the total number of carbons of the R^XC or R²C portion in formula (3), is 22. Thus, when the total number of carbons of the fatty acid composing the diester of the pentaerythritol and fatty acid is

approximately 22 or greater, the IOB satisfies the condition of being within about 0.00 to 0.60.

[0089]

In a monoester of pentaerythritol and a fatty acid, the IOB is 0.60 if the total number of carbons of the fatty acid composing the monoester of the pentaerythritol and fatty acid, i.e., the total number of carbons of the R^XC portion in formula (4), is 25. Thus, when the number of carbons of the fatty acid composing the monoester of the pentaerythritol and fatty acid is approximately 25 or greater, the IOB satisfies the condition of being within about 0.00 to 0.60.

The effects of double bonds, triple bonds, iso- branches and tert-branches are not considered in this calculation.

[0090]

Commercial products which are esters of

pentaerythritol and fatty acids include UNISTAR H-408BRS and H-2408BRS-22 (mixed product) (both products of NOF Corp. ) .

[0091 ]

[ (a₂) Ester of a chain hydrocarbon triol and at least one fatty acid]

Examples of esters of a chain hydrocarbon triol and at least one fatty acid include triesters of glycerin and fatty acids, represented by formula (5) :

CH₂OOCR⁵

I

CHOOCR⁶ (5)

I

CH₂OOCR⁷ diesters of glycerin and fatty acids, represented by the following formula (6) :

CH₂OOCR⁵ CH₂OOCR⁵

I I

CHOH or CHOOCR⁶ (6)

I I

CH₂OOCR⁶ CH₂OH

and monoesters of glycerin and fatty acids, represented by the following formula (7):

CH₂OOCR⁵ CH₂OH

I I

CHOH or CHOOCR⁵ (7)

I I CH₂OH CH₂OH

wherein R⁵-R⁷ each represent a chain hydrocarbon.

[0092]

The fatty acid composing the ester of glycerin and a fatty acid (R⁵COOH, R⁶COOH and R⁷COOH) is not particularly restricted as long as the ester of glycerin and a fatty acid satisfies the conditions for the IOB, melting point and water solubility, and for example, there may be mentioned the fatty acids mentioned for the " (ai) Ester of chain hydrocarbon tetraol and at least one fatty acids", namely saturated fatty acids and unsaturated fatty acids, and in consideration of the potential for degradation by oxidation and the like, the ester is preferably a

glycerin and fatty acid ester, which is derived from a saturated fatty acid, i.e., an ester of glycerin and a saturated fatty acid.

Also, in order to lower the IOB and result in greater hydrophobicity, the ester of glycerin and a fatty acid is preferably a diester or triester, and more preferably a triester.

[0093]

A triester of glycerin and a fatty acid is also known as a triglyceride, and examples include triesters of glycerin and octanoic acid (Cs) , triesters of glycerin and decanoic acid (Ci₀) , triesters of glycerin and

dodecanoic acid (C12) , triesters of glycerin and 2 or more different fatty acids, and mixtures of the foregoing.

[0094]

Examples of triesters of glycerin and 2 or more fatty acids include triesters of glycerin with octanoic acid (C₈) and decanoic acid (C10) , triesters of glycerin with octanoic acid (C₈) , decanoic acid (Ci₀) and

dodecanoic acid (C12) , and triesters of glycerin with octanoic acid (C_g) , decanoic acid (Ci₀) , dodecanoic acid (C12) , tetradecanoic acid (C14) , hexadecanoic acid (Ci₆) and octadecanoic acid (Cig) .

[0095]

In order to obtain a melting point of no higher than about 45°C, preferred triesters of glycerin and fatty acids are those with no more than about 40 as the total number of carbons of the fatty acid composing the

triester of glycerin and the fatty acid, i.e., the total number of carbons of the R⁵C, R⁶C and R⁷C portions in formula (5) .

[0096]

In a triester of glycerin and a fatty acid, the IOB value is 0.60 when the total number of carbons of the fatty acid composing the triester of glycerin and the fatty acid, i.e., the total number of carbons of the R⁵C, R⁶C and R⁷C portions in formula (5), is 12. Thus, when the total number of carbons of the fatty acid comprising the triester of the glycerin and fatty acid is

approximately 12 or greater, the IOB satisfies the condition of being within about 0.00 to 0.60.

Triesters of glycerin and fatty acids, being

aliphatic and therefore potential constituent components of the human body are preferred from the viewpoint of safety.

[0097]

Commercial products of triesters of glycerin and fatty acids include tri-coconut fatty acid glycerides, NA36, PANACET 800, PANACET 800B and PANACET 810S, and tri-C2L oil fatty acid glycerides and tri-CL oil fatty acid glycerides (all products of NOF Corp.).

[0098]

A diester of glycerin and a fatty acid is also known as a diglyceride, and examples include diesters of glycerin and decanoic acid (Ci₀) , diesters of glycerin and dodecanoic acid (Ci₂) , diesters of glycerin and

hexadecanoic acid (Ci6) , diesters of glycerin and 2 or more different fatty acids, and mixtures of the

foregoing.

In a diester of glycerin and a fatty acid, the IOB is 0.58 if the total number of carbons of the fatty acid composing the diester of the glycerin and fatty acid, i.e., the total number of carbons of the R⁵C and R⁶C portions in formula (6), is 16. Thus, when the total number of carbons of the fatty acid composing the diester of the glycerin and fatty acid is approximately 16 or greater, the IOB satisfies the condition of being about

0.00 to 0.60.

[0099]

Monoesters of glycerin and fatty acids are also known as monoglycerides, and examples include glycerin and icosanoic acid (C₂₀) monoester, and glycerin and docosanoic acid (C22) monoester.

In a monoester of glycerin and a fatty acid, the IOB is 0.59 if the number of carbons of the fatty acid composing the monoester of the glycerin and fatty acid,

1. e., the number of carbons of the R⁵C portion in formula (7), is 19. Thus, when the number of carbons of the fatty acid composing the monoester of the glycerin and fatty acid is approximately 19 or greater, the IOB satisfies the condition of being about 0.00 to 0.60.

[0100]

[ (a3) Ester of chain hydrocarbon diol and at least one fatty acid]

Examples of an ester of a chain hydrocarbon diol and at least one fatty acids include monoesters and diesters of fatty acids with C₂-C6 chain hydrocarbon diols, such as C2^_C₆ glycols, including ethylene glycol, propylene glycol, butylene glycol, pentylene glycol and hexylene glycol .

[0101]

Specifically, examples of an ester of a chain hydrocarbon diol and at least one fatty acid include diesters of C₂-C₆ glycols and fatty acids, represented by the following formula (8):

R⁸COOC_kH_2kOCOR⁹ (8)

wherein k represents an integer of 2-6, and R⁸ and R⁹ each represent a chain hydrocarbon,

and monoesters of C₂-C₆ glycols and fatty acids,

represented by the following formula (9):

R⁸COOC_kH_2kOH (9)

wherein k represents an integer of 2-6, and R⁸ is a chain hydrocarbon. [0102]

The fatty acid to be esterified in an ester of a C₂- C₆ glycol and a fatty acid (corresponding to R⁸C00H and R⁹COOH in formula (8) and formula (9)) is not particularly restricted so long as the ester of the C2~C₆ glycol and fatty acid satisfies the conditions for the IOB, melting point and water solubility, and for example, there may be mentioned the fatty acids mentioned for the " (ai) Ester of a chain hydrocarbon tetraol and at least one fatty acid", namely saturated fatty acids and unsaturated fatty acids, and in consideration of the potential for degradation by oxidation and the like, it is preferably a saturated fatty acid.

[0103]

In a diester of butylene glycol (k = 4) and a fatty acid represented by formula (8), IOB is 0.60 when the total number of carbons of the R⁸C and R⁹C portions is 6. Thus, when the total number of carbon atoms in a diester of butylene glycol (k = 4) and a fatty acid represented by formula (8) is approximately 6 or greater, the IOB satisfies the condition of being about 0.00-0.60. In a monoester of ethylene glycol (k = 2) and a fatty acid represented by formula (9), IOB is 0.57 when the number of carbons of the R⁸C portion is 12. Thus, when the total number of carbon atoms in the fatty acid composing a monoester of ethylene glycol (k = 2) and a fatty acid represented by formula (9) is approximately 12 or

greater, the IOB satisfies the condition of being about 0.00-0.60.

[0104]

Considering the potential for degradation by

oxidation and the like, the ester of the C₂-C₅ glycol and fatty acid is preferably a C₂-C₆ glycol and fatty acid ester, which is derived from a saturated fatty acid, i.e., an ester of a C₂-C₆ glycol and a saturated fatty acid.

[0105] Also, in order to lower the IOB and result in greater hydrophobicity, the ester of the ₂- e glycol and fatty acid is preferably a glycol and fatty acid ester derived from a glycol with a greater number of carbons, such as an ester of a glycol and a fatty acid derived from butylene glycol, pentylene glycol or hexylene glycol .

Also, in order to lower the IOB and obtain in greater hydrophobicity, the ester of a C₂-C₆ glycol and fatty acid is preferably a diester.

Examples of commercial products of esters of C₂-C₆ glycols and fatty acids include COMPOL BL and COMPOL BS (both products of NOF Corp.) .

[0106]

[ (B) Ether of (Bl) a compound having a chain hydrocarbon moiety and 2-4 hydroxyl groups substituting hydrogens on the chain hydrocarbon moiety and (B2) a compound having a chain hydrocarbon moiety and 1 hydroxyl group

substituting a hydrogen on the chain hydrocarbon moiety] The (B) ether of (Bl) a compound having a chain hydrocarbon moiety and 2-4 hydroxyl groups substituting hydrogens on the chain hydrocarbon moiety and (B2) a compound having a chain hydrocarbon moiety and 1 hydroxyl group substituting a hydrogen on the chain hydrocarbon moiety (hereunder also referred to as "compound (B)") includes ethers of a compound with 4, 3 or 2 hydroxyl groups and a compound with 1 hydroxyl group, and it is not necessary for all of the hydroxyl groups to be etherified as long as the IOB, melting point and water solubility are within the aforementioned ranges.

[0107]

Examples of (Bl) a compound having a chain

hydrocarbon moiety and 2-4 hydroxyl groups substituting hydrogens on the chain hydrocarbon moiety (hereunder also referred to as "compound (Bl)") include those mentioned for "compound (A)",)" as compound (Al) , such as

pentaerythritol, glycerin and glycol. Examples of (B2) a compound having a chain

hydrocarbon moiety and 1 hydroxyl group substituting a hydrogen on the chain hydrocarbon moiety (hereunder also referred to as "compound (B2)") include compounds wherein 1 hydrogen on the hydrocarbon is substituted with 1 hydroxyl group (-OH) , such as aliphatic monohydric alcohols, including saturated aliphatic monohydric alcohols and unsaturated aliphatic monohydric alcohols.

[0108]

Examples of saturated aliphatic monohydric alcohols include Ci-C₂o saturated aliphatic monohydric alcohols, such as methyl alcohol (Ci) (Ci representing the number of carbon atoms, same hereunder) , ethyl alcohol (C2) , propyl alcohol (C₃) and isomers thereof, including isopropyl alcohol (C₃) , butyl alcohol (C₄) and isomers thereof, including sec-butyl alcohol (C4) and tert-butyl alcohol (C₄) , pentyl alcohol (C₅) , hexyl alcohol (C₆) , heptyl alcohol (C₇) , octyl alcohol (C_g) and isomers thereof, including 2-ethylhexyl alcohol (C₈) , nonyl alcohol (Cg) , decyl alcohol (C10) , dodecyl alcohol (Ci₂) , tetradecyl alcohol (C14) , hexadecyl alcohol (Ci₆) , heptadecyl alcohol (C17) , octadecyl alcohol (Ci₈) and eicosyl alcohol (C₂o) as well as their isomers other than those mentioned.

Unsaturated aliphatic monohydric alcohols include those wherein 1 C-C single bond of a saturated aliphatic monohydric alcohol mentioned above is replaced with a C=C double bond, such as oleyl alcohol, and for example, these are commercially available by New Japan Chemical Co., Ltd. as the RIKACOL Series and U JECOL Series.

[0109]

Examples for compound (B) include (bi) an ether of a chain hydrocarbon tetraol and at least one aliphatic monohydric alcohol, such as monoethers, diethers,

triethers and tetraethers, preferably diethers, triethers and tetraethers, more preferably triethers and

tetraethers and even more preferably tetraethers, (b₂) an ether of a chain hydrocarbon triol and at least one aliphatic monohydric alcohol, such as monoethers, diethers and triethers, preferably diethers and triethers and more preferably triethers, and (b₃) an ether of a chain hydrocarbon diol and at least one aliphatic

monohydric alcohols, such as monoethers and diethers, and preferably diethers.

[0110]

Examples of an ether of a chain hydrocarbon tetraol and at least one aliphatic monohydric alcohols include tetraethers, triethers, diethers and monoethers of pentaerythritol and aliphatic monohydric alcohols, represented by the following formulae (10) -(13):

wherein R -R each represent a chain hydrocarbon.

[0111]

Examples of an ether of a chain hydrocarbon triol and at least one aliphatic monohydric alcohol include triethers, diethers and monoethers of glycerin and aliphatic monohydric alcohols, represented by the

following formulae (14) -(16): CH₂OR¹⁴

I

CHOR¹⁵

I

CH₂OR¹⁶

CH₂OR¹⁴ CH₂OH

I I

CHOH or CHOR¹⁴ ( 1 6)

I I CH₂OH CH₂OH

wherein R^14~R¹⁶ each represent a chain hydrocarbon.

[0112]

Examples of an ether of a chain hydrocarbon diol and at least one aliphatic monohydric alcohol include

diethers of C2-C6 glycols and aliphatic monohydric alcohols, represented by the following formula (17):

R¹⁷OC_nH_2nOR¹⁸ (17)

wherein n is an integer of 2-6, and R¹⁷ and R¹⁸ are each a chain hydrocarbon,

and monoethers of C₂-C₆ glycols and aliphatic monohydric alcohols, represented by the following formula (18):

R¹⁷OC_nH_2nOH (18)

wherein n is an integer of 2-6, and R¹⁷ is a chain hydrocarbon.

[0113]

In the tetraether of pentaerythritol and an

aliphatic monohydric alcohol, the IOB is 0.44 when the total number of carbon atoms of the aliphatic monohydric alcohol composing the tetraether of pentaerythritol and the aliphatic monohydric alcohol, i.e., the total number of carbon atoms of the R¹⁰, R¹¹, R¹² and R¹³ portions in formula (10), is 4. Thus, when the total number of carbon atoms of the aliphatic monohydric alcohol

composing a tetraether of pentaerythritol and an aliphatic monohydric alcohol is approximately 4 or greater, the IOB value satisfies the condition of being within about 0.00 to 0.60.

[0114]

In the triether of pentaerythritol and an aliphatic monohydric alcohol, the IOB is 0.57 when the total number of carbon atoms of the aliphatic monohydric alcohol composing the triether of pentaerythritol and the

aliphatic monohydric alcohol, i.e., the total number of carbon atoms of the R¹⁰, R¹¹ and R¹² portions in formula

(11), is 9. Thus, when the total number of carbon atoms of the aliphatic monohydric alcohol composing a triether of pentaerythritol and an aliphatic monohydric alcohol is approximately 9 or greater, the IOB value satisfies the condition of being within about 0.00 to 0.60.

[0115]

In the diether of pentaerythritol and an aliphatic monohydric alcohol, the IOB is 0.60 when the total number of carbon atoms of the aliphatic monohydric alcohol composing the diether of pentaerythritol and the

aliphatic monohydric alcohol, i.e., the total number of carbon atoms of the R¹⁰ and R¹¹ portions in formula (12), is 15. Thus, when the total number of carbon atoms of the aliphatic monohydric alcohol composing a diether of pentaerythritol and an aliphatic monohydric alcohol is approximately 15 or greater, the IOB value satisfies the condition of being within about 0.00 to 0.60.

[0116]

In the monoether of pentaerythritol and an aliphatic monohydric alcohol, the IOB is 0.59 when the number of carbon atoms of the aliphatic monohydric alcohol

composing the monoether of pentaerythritol and the aliphatic monohydric alcohol, i.e., the number of carbon atoms of the R¹⁰ portion in formula (13), is 22. Thus, when the number of carbon atoms of the aliphatic

monohydric alcohol comprising a monoether of

pentaerythritol and an aliphatic monohydric alcohol is approximately 22 or greater, the IOB value satisfies the condition of being within about 0.00 to 0.60.

[0117]

In the triether of glycerin and an aliphatic monohydric alcohol, the IOB is 0.50 when the total numbe of carbon atoms of the aliphatic monohydric alcohol composing the triether of glycerin and the aliphatic monohydric alcohol, i.e., the total number of carbon atoms of the R¹⁴, R¹⁵ and R¹⁶ portions in formula (14), is 3. Thus, when the total number of carbon atoms of the aliphatic monohydric alcohol comprising a triether of glycerin and an aliphatic monohydric alcohol is

approximately 3 or greater, the IOB value satisfies the condition of being within about 0.00 to 0.60.

[0118]

In the diether of glycerin and an aliphatic

monohydric alcohol, the IOB is 0.58 when the total numbe of carbon atoms of the aliphatic monohydric alcohol composing the diether of glycerin and the aliphatic monohydric alcohol, i.e., the total number of carbon atoms of the R¹⁴ and R¹⁵ portions in formula (15), is 9. Thus, when the total number of carbon atoms of the aliphatic monohydric alcohol comprising a diether of glycerin and an aliphatic monohydric alcohol is

approximately 9 or greater, the IOB value satisfies the condition of being within about 0.00 to 0.60.

[0119]

In the monoether of glycerin and an aliphatic monohydric alcohol, the IOB is 0.58 when the number of carbon atoms of the aliphatic monohydric alcohol

composing the monoether of glycerin and the aliphatic monohydric alcohol, i.e., the number of carbon atoms of the R¹⁴ portion in formula (16), is 16. Thus, when the number of carbon atoms of the aliphatic monohydric alcohol comprising a monoether of glycerin and an aliphatic monohydric alcohol is approximately 16 or greater, the IOB value satisfies the condition of being within about 0.00 to 0.60.

[0120]

In a diether of butylene glycol (n = 4) and

aliphatic monohydric alcohol represented by formula (17), the IOB is 0.33 when the total number of carbon atoms of the R¹⁷ and R¹⁸ portions is 2. Thus, when the number of carbon atoms of the aliphatic monohydric alcohol

comprising a diether of butylene glycol (n = 4) and an aliphatic monohydric alcohol represented by formula (17) is approximately 2 or greater, the IOB value satisfies the condition of being within about 0.00 to 0.60. Also, in a monoether of ethylene glycol (n = 2) and aliphatic monohydric alcohol represented by formula (18), the IOB is 0.60 when the number of carbon atoms of the R¹⁷ portion is 8. Thus, when the number of carbon atoms of the aliphatic monohydric alcohol in a monoether of ethylene glycol (n = 2) and an aliphatic monohydric alcohol represented by formula (18) is approximately 8 or

greater, the IOB value satisfies the condition of being within about 0.00 to 0.60.

[0121]

Compound (B) may be produced by dehydrating

condensation of a compound with 2-4 hydroxyl groups (Bl) and a compound with 1 hydroxyl group, such as an

aliphatic monohydric alcohol (B2), in the presence of an acid catalyst.

[0122]

[ (C) Ester of (Cl) a carboxylic acid, hydroxy acid, alkoxy acid or oxoacid comprising a chain hydrocarbon moiety and 2-4 carboxyl groups substituting hydrogens on the chain hydrocarbon moiety and (C2) a compound having a chain hydrocarbon moiety and 1 hydroxyl group

substituting a hydrogen on the chain hydrocarbon moiety] The (C) ester of (Cl) a carboxylic acid, hydroxy acid, alkoxy acid or oxoacid comprising a chain

hydrocarbon moiety and 2-4 carboxyl groups substituting hydrogens on the chain hydrocarbon moiety and (C2) a compound having a chain hydrocarbon moiety and 1 hydroxyl group substituting a hydrogen on the chain hydrocarbon moiety (hereunder also referred to as "compound (C)") includes esters of a compound with 4, 3 or 2 carboxyl groups and a compound with 1 hydroxyl group, and it is not necessary for all of the carboxyl groups to be esterified so long as the IOB, melting point and water solubility are within the aforementioned ranges.

[0123]

Examples of (CI) a carboxylic acid, hydroxy acid, alkoxy acid or oxoacid comprising a chain hydrocarbon moiety and 2-4 carboxyl groups substituting hydrogens on the chain hydrocarbon moiety (hereunder also referred to as "compound (CI)") include chain hydrocarbons

hydrocarbon carboxylic acids with 2-4 carboxyl groups, such as chain hydrocarbon dicarboxylic acids including alkanedicarboxylic acids such as ethanedioic acid, propanedioic acid, butanedioic acid, pentanedioic acid, hexanedioic acid, heptanedioic acid, octanedioic acid, nonanedioic acid and decanedioic acid, chain hydrocarbon tricarboxylic acids, including alkanetricarboxylic acids such as propanetrioic acid, butanetrioic acid,

pentanetrioic acid, hexanetrioic acid, heptanetrioic acid, octanetrioic acid, nonanetrioic acid and

decanetrioic acid, and chain hydrocarbon tetracarboxylic acids, including alkanetetracarboxylic acids such as butanetetraoic acid, pentanetetraoic acid, hexanetetraoic acid, heptanetetraoic acid, octanetetraoic acid,

nonanetetraoic acid and decanetetraoic acid.

[0124]

Compound (CI) includes chain hydrocarbon hydroxy acids with 2-4 carboxyl groups, including alkoxy acids with 2-4 carboxyl groups such as malic acid, tartaric acid, citric acid and isocitric acid, including chain hydrocarbon alkoxy acids with 2-4 carboxyl groups, such as O-acetylcitric acid, and chain hydrocarbon oxoacids with 2-4 carboxyl groups. Compounds (C2) having a chain hydrocarbon moiety and 1 hydroxyl group substituting a hydrogen on the chain hydrocarbon moiety include those mentioned for the

"compound (B) ", such as aliphatic monohydric alcohols.

[0125]

Compound (C) may be (c_x) an ester, for example a monoester, diester, triester or tetraester, preferably a diester, triester or tetraester, more preferably a triester or tetraester and even more preferably a

tetraester, of a chain hydrocarbon tetracarboxylic acid, hydroxy acid, alkoxy acid or oxoacid with 4 carboxyl groups, and at least one aliphatic monohydric alcohol, (C2) an ester, for example, a monoester, diester or triester, preferably a diester or triester and more preferably a triester, of a chain hydrocarbon

tricarboxylic acid, hydroxy acid, alkoxy acid or oxoacid with 3 carboxyl groups, and at least one aliphatic monohydric alcohol, or (c₃) an ester, for example, a monoester or diester, and preferably a diester, of a chain hydrocarbon dicarboxylic acid, hydroxy acid, alkoxy acid or oxoacid with 2 carboxyl groups, and at least one aliphatic monohydric alcohol.

Examples for compound (C) include dioctyl adipate and tributyl O-acetylcitrate, of which commercially available products exist.

[0126]

[ (D) Compound having a chain hydrocarbon moiety and one bond selected from the group consisting of an ether bond (-0-) , carbonyl bond (-CO-), ester bond (-C00-) and carbonate bond (-OCOO-) inserted in a chain hydrocarbon moiety and one bond selected from the group consisting of an ether bond (-0-) , carbonyl bond (-CO-), ester bond (- COO-) and carbonate bond (-OCOO-) inserted between a C-C single bond of the chain hydrocarbon moiety]

The (D) compound having a chain hydrocarbon moiety and one bond selected from the group consisting of an ether bond (-0-) , carbonyl bond (-CO-), ester bond (-COO- ) and carbonate bond (-OCOO-) inserted in-between a C-C single bond of the chain hydrocarbon moiety (hereunder also referred to as "compound (D)") may be (di) an ether of an aliphatic monohydric alcohol and an aliphatic monohydric alcohol, (d2) a dialkyl ketone, (d₃) an ester of a fatty acid and an aliphatic monohydric alcohol, or (d₄) a dialkyl carbonate.

[0127]

[ (di) Ether of an aliphatic monohydric alcohol and an aliphatic monohydric alcohol]

Ethers of aliphatic monohydric alcohols and

aliphatic monohydric alcohols include compounds having the following formula (19) :

Ri9_OR2o _{( 19 )}

wherein R¹⁹ and R²⁰ each represent a chain

hydrocarbon .

[0128]

The aliphatic monohydric alcohol composing the ether (corresponding to R¹⁹OH and R²⁰OH in formula (19)) is not particularly restricted so long as the ether satisfies the conditions for the IOB, melting point and water solubility, and for example, it may be one of the

aliphatic monohydric alcohols mentioned for "compound (B)".

[0129]

In an ether of an aliphatic monohydric alcohol and an aliphatic monohydric alcohol, the IOB is 0.50 when the total number of carbon atoms of the aliphatic monohydric alcohols composing the ether, i.e., the total number of carbons of the R¹⁹ and R²⁰ portions in formula (19), is 2, and therefore when the total number of carbons of the aliphatic monohydric alcohols comprising the ether is about 2 or greater, this condition for the IOB is

satisfied. However, when the total number of carbons of the aliphatic monohydric alcohols comprising the ether is about 6, the water solubility is as high as about 2 g, which is problematic from the viewpoint of vapor pressure as well. In order to satisfy the condition of a water solubility of about 0.00-0.05 g, the total number of carbons of the aliphatic monohydric alcohols comprising the ether is preferably about 8 or greater.

[0130]

[ (d₂) Dialkyl ketone]

The dialkyl ketone may be a compound of the

following formula (20):

R2i_COR22 ₍₂₀₎

wherein R²¹ and R²² are each an alkyl group.

[0131]

In a dialkyl ketone, the IOB is 0.54 when the total number of carbon atoms of R²¹ and R²² is 5, and therefore this condition for the IOB is satisfied if the total number of carbons is about 5 or greater. However, when the total number of carbons of dialkyl ketone is about 5, the water solubility is as high as about 2 g. Therefore, in order to satisfy the condition of a water solubility of about 0.00-0.05 g, the total number of carbons of dialkyl ketone is preferably about 8 or greater. In consideration of vapor pressure, the number of carbon atoms of dialkyl ketone is preferably about 10 or greater and more preferably about 12 or greater.

If the total number of carbon atoms of alkyl ketone is about 8, such as in 5-nonanone, for example, the melting point is approximately -50°C and the vapor pressure is about 230 Pa at 20°C.

The dialkyl ketone may be a commercially available product, or it may be obtained by a known method, such as by oxidation of a secondary alcohol with chromic acid or the like.

[0132]

[ (d₃) Ester of a fatty acid and an aliphatic monohydric alcohol]

Examples of esters of fatty acids and aliphatic monohydric alcohols include compounds having the

following formula (21) : R²³COOR²⁴ (21)

wherein R²³ and R²⁴ each represent a chain

hydrocarbon .

[0133]

Examples of fatty acids composing these esters

(corresponding to R²³COOH in formula (21) ) include the fatty acids mentioned for the " (ai) an ester of a chain hydrocarbon tetraol and at least one fatty acids", and specifically these include saturated fatty acids and unsaturated fatty acids, with saturated fatty acids being preferred in consideration of the potential for

degradation by oxidation and the like. The aliphatic monohydric alcohol composing the ester (corresponding to R²⁴OH in formula (21) ) may be one of the aliphatic

monohydric alcohols mentioned for "compound (B)".

[0134]

In an ester of such a fatty acid and aliphatic monohydric alcohol, the IOB is 0.60 when the total number of carbon atoms of the fatty acid and aliphatic

monohydric alcohol, i.e., the total number of carbon atoms of the R²³C and R²⁴ portion in formula (21) , is 5, and therefore this condition for the IOB is satisfied when the total number of carbon atoms of the R²³C and R²⁴ portion is about 5 or greater. However, with butyl acetate in which the total number of carbon atoms is 6, the vapor pressure is high at greater than 2000 Pa. In consideration of vapor pressure, therefore, the total number of carbon atoms is preferably about 12 or greater. If the total number of carbon atoms is about 11 or greater, it will be possible to satisfy the condition of a water solubility of about 0.00-0.05 g.

[0135]

Examples of esters of such fatty acids and aliphatic monohydric alcohols include esters of dodecanoic acid (Ci₂) and dodecyl alcohol (Ci₂) and esters of tetradecanoic acid (C14) and dodecyl alcohol (C_i2) , and examples of commercial products of esters of such fatty acids and aliphatic monohydric alcohols include ELECTOL WE20 and

ELECTOL E40 (both products of NOF Corp.).

[0136]

[ (d₄) Dialkyl carbonate]

The dialkyl carbonate may be a compound of the following formula (22):

R²⁵OC(=0)OR²⁶ (22)

wherein R²⁵ and R²⁶ are each an alkyl group.

[0137]

In a dialkyl carbonate, the IOB is 0.57 when the total number of carbon atoms of R²⁵ and R²⁶ is 6, and therefore this condition for the IOB is satisfied if the total number of carbons of R²⁵ and R²⁶ is about 6 or greater.

In consideration of water solubility, the total number of carbon atoms of R²⁵ and R²⁶ is preferably about 7 or greater and more preferably about 9 or greater.

The dialkyl carbonate may be a commercially

available product, or it may be synthesized by reaction between phosgene and an alcohol, reaction between formic chloride and an alcohol or alcoholate, or reaction between silver carbonate and an alkyl iodide.

[0138]

[ (E) Polyoxy C₂-C₆ alkylene glycol, or alkyl ester or alkyl ether thereof]

The (E) polyoxy C₂_₆ alkylene glycol, or alkyl ester or alkyl ether thereof (hereunder also referred to as "compound (E)") may be (ei) a polyoxy C₂-6 alkylene glycol, (e₂) an ester of a polyoxy C₂-6 alkylene glycol and at least one fatty acid, (e3) an ether of a polyoxy C₂-6 alkylene glycol and at least one aliphatic monohydric alcohol, (e₄) an ester of polyoxy C₂-6 alkylene glycol and chain hydrocarbon tetracarboxylic acid, chain hydrocarbon tricarboxylic acid or chain hydrocarbon dicarboxylic acid, or (e₅) an ether of polyoxy G₂_₆ alkylene glycol and chain hydrocarbon tetraol, chain hydrocarbon triol or chain hydrocarbon diol. These will now be explained. [0139]

[ (ei) Polyoxy C₂-C₆ alkylene glycol]

The polyoxy C₂-C₆ alkylene glycol is i) a homopolymer having one backbone selected from the group consisting of polyoxy C₂-C& alkylene backbones, i.e. oxyethylene

backbone, oxypropylene backbone, oxybutylene backbone, oxypentylene backbone and oxyhexylene backbone, and having hydroxy groups at both ends, ii) a block copolymer having a backbone of 2 or more selected from among the aforementioned group and having hydroxy groups at both ends, or iii) a random copolymer having a backbone of two or more selected from among the aforementioned group and having hydroxy groups at both ends.

[0140]

The polyoxy 0₂-0₆ alkylene backbone is preferably an oxypropylene backbone, oxybutylene backbone, oxypentylene backbone or oxyhexylene backbone and more preferably an oxybutylene backbone, oxypentylene backbone or

oxyhexylene backbone, from the viewpoint of lowering the IOB of the polyoxy C₂-C alkylene glycol.

[0141]

When polyoxy C₂-Ce alkylene glycol is a homopolymer, the poly C₃-₆ alkylene glycol is represented by the following formula (23) :

HO-(C_raH_2mO)_n-H (23)

wherein m is an integer of 3-6.

[0142]

The present inventors have confirmed that in

polyethylene glycol (corresponding to formula (23) where m = 2), when n > 45 (the molecular weight exceeds about

2,000), the condition for IOB of about 0.00 to about 0.60 is satisfied, but the condition for the water solubility is not satisfied even when the molecular weight exceeds 4,000. Therefore, ethylene glycol homopolymer is not included in the (ei) polyoxy C₂~e alkylene glycol, and ethylene glycol should be included in the (ei) polyoxy C₂-6 alkylene glycol only as a copolymer or random polymer with another glycol.

[0143]

Thus, homopolymers of formula (23) may include propylene glycol, butylene glycol, pentylene glycol or hexylene glycol homopolymer.

For this reason, m in formula (23) is about 3 to 6 and preferably about 4 to 6, and n is 2 or greater.

[0144]

The value of n in formula (23) is a value such that the polyoxy C₂-e alkylene glycol has an IOB of about 0.00-

0.60, a melting point of no higher than about 45°C and a water solubility of no greater than about 0.05 g in 100 g of water at 25°C.

For example, when formula (23) is polypropylene glycol (m = 3), the IOB is 0.58 when n = 12. Thus, when formula (23) is polypropylene glycol (m = 3) , the

condition for the IOB is satisfied when n is equal to or greater than about 12.

Also, when formula (23) is polybutylene glycol (m = 4), the IOB is 0.57 when n = 7. Thus, when formula (23) is polybutylene glycol (m = 4), the condition for the IOB is satisfied when n is equal to or greater than about 7.

[0145]

From the viewpoint of IOB, melting point and water solubility, the weight-average molecular weight of the polyoxy C₂-6 alkylene glycol is preferably between about 200 and about 10,000, more preferably between about 250 and about 8,000, and even more preferably in the range of about 250 to about 5,000.

Also from the viewpoint of IOB, melting point and water solubility, the weight-average molecular weight of a poly C₃ alkylene glycol, i.e. polypropylene glycol, is preferably between about 1,000 and about 10,000, more preferably between about 3,000 and about 8,000, and even more preferably between about 4,000 and about 5,000.

This is because if the weight-average molecular weight is less than about 1,000, the condition for the water solubility will not be satisfied, and a larger weight- average molecular weight will particularly tend to increase the migration rate into the absorbent body and the whiteness of the top sheet.

[0146]

Examples of commercial products of polyoxy C₂_₆ alkylene glycols include UNIOL™ D-1000, D1200, D-2000, D- 3000, D-4000, PB-500 and PB-700 (both products of NOF Corp . ) .

[0147]

[ (e₂) Ester of polyoxy C₂-e alkylene glycol and at least one fatty acid]

Esters of such polyoxy C₂-6 alkylene glycols and at least one fatty acid include the polyoxy C₂-6 alkylene glycols mentioned for " (ei) Polyoxy C₂-e alkylene glycol" in which one or both OH ends have been esterified with fatty acids, i.e., monoesters and diesters.

[0148]

Examples of fatty acids to be esterified in the ester of a polyoxy C₂-6 alkylene glycol and at least one fatty acid include the fatty acids mentioned for the " (ai) Esters of chain hydrocarbon tetraols and at least one fatty acid", and specifically these include saturated fatty acids and unsaturated fatty acids, with saturated fatty acids being preferred in consideration of the potential for degradation by oxidation and the like. An example of a commercially available ester of a polyoxy C₂_ 6 alkylene glycol and a fatty acid is WILLBRITE cp9

(product of NOF Corp.).

[0149]

[ (e₃) Ether of polyoxy C₂-6 alkylene glycol and at least one aliphatic monohydric alcohol]

Ethers of such polyoxy C₂_₆ alkylene glycols and at least one aliphatic monohydric alcohol include the polyoxy C₂_₆ alkylene glycols mentioned for " (ei) polyoxy C₂_6 alkylene glycol" wherein one or both OH ends have been etherified by an aliphatic monohydric alcohol, i.e., monoethers and diethers.

In an ether of a polyoxy C₂-6 alkylene glycol and at least one aliphatic monohydric alcohol, the aliphatic monohydric alcohol to be etherified may be an aliphatic monohydric alcohol among those mentioned for "compound (B)".

[0150]

[ (e₄) Ester of polyoxy C₂-₆ alkylene glycol and chain hydrocarbon tetracarboxylic acid, chain hydrocarbon tricarboxylic acid or chain hydrocarbon dicarboxylic acid]

The polyoxy C2-6 alkylene glycol to be esterified for the aforementioned ester of a polyoxy C₂_₆ alkylene glycol and a chain hydrocarbon tetracarboxylic acid, chain hydrocarbon tricarboxylic acid or chain hydrocarbon dicarboxylic acid may be any of the polyoxy C₂-6 alkylene glycols mentioned above under " (ei) Polyoxy C₂-6 alkylene glycol". Also, the chain hydrocarbon tetracarboxylic acid, chain hydrocarbon tricarboxylic acid or chain hydrocarbon dicarboxylic acid to be esterified may be any of those mentioned above for "compound (C)".

[0151]

The ester of a polyoxy C₂-6 alkylene glycol and a chain hydrocarbon tetracarboxylic acid, chain hydrocarbon tricarboxylic acid or chain hydrocarbon dicarboxylic acid may be a commercially available product, or it may be produced by polycondensation of a polyoxy C₂-6 alkylene glycol with a chain hydrocarbon tetracarboxylic acid, chain hydrocarbon tricarboxylic acid or chain hydrocarbon dicarboxylic acid under known conditions.

[0152]

[ (e5) Ether of polyoxy C₂-6 alkylene glycol and chain hydrocarbon tetraol, chain hydrocarbon triol or chain hydrocarbon diol]

The polyoxy C2- 6 alkylene glycol to be etherified for the aforementioned ether of a polyoxy C₂-6 alkylene glycol and a chain hydrocarbon tetraol, chain hydrocarbon triol or chain hydrocarbon diol may be any of the polyoxy C₂-6 alkylene glycols mentioned above under " (ei) Polyoxy C₂-6 alkylene glycol". Also, the chain hydrocarbon tetraol, chain hydrocarbon triol or chain hydrocarbon diol to be etherified may be, for example, pentaerythritol, glycerin or glycol, mentioned above for "compound (A)".

[0153]

Examples of commercially available ethers of polyoxy

C₂-6 alkylene glycols and chain hydrocarbon tetraols, chain hydrocarbon triols and chain hydrocarbon diols include UNILUBE™ 5TP-300KB and UNIOL™ TG-3000 and TG-4000

(products of NOF Corp.).

UNILUBE™ 5TP-300KB is a compound obtained by

polycondensation of 65 mol of propylene glycol and 5 mol of ethylene glycol with 1 mol of pentaerythritol, and it has an IOB of 0.39, a melting point of below 45°C, and a water solubility of less than 0.05 g.

[0154]

UNIOL™ TG-3000 is a compound obtained by

polycondensation of 50 mol of propylene glycol with 1 mol of glycerin, and it has an IOB of 0.42, a melting point of below 45°C, a water solubility of less than 0.05 g, and a weight-average molecular weight of about 3,000.

UNIOL™ TG-4000 is a compound obtained by

polycondensation of 70 mol of propylene glycol with 1 mol of glycerin, and it has an IOB of 0.40, a melting point of below 45°C, a water solubility of less than 0.05 g, and a weight-average molecular weight of about 4,000.

[0155]

The ether of a poly C₂-6 alkylene glycol and a chain hydrocarbon tetraol, chain hydrocarbon triol or chain hydrocarbon diol may also be produced by polycondensation of a polyoxy C₂_₆ alkylene glycol with a chain hydrocarbon tetraol, chain hydrocarbon triol or chain hydrocarbon diol under known conditions.

[0156] [ (F) Chain hydrocarbon]

The chain hydrocarbon has an inorganic value of 0 and thus an IOB of 0.00, while the water solubility is also approximately 0 g, and therefore if the melting point is no higher than about 45°C, it may be included among the aforementioned blood modifying agents.

Examples of such chain hydrocarbons include (fi) chain alkanes, such as linear alkanes and branched alkanes, and linear alkanes generally include those with no more than 22 carbons, in consideration of a melting point of no higher than about 45°C. In consideration of vapor pressure, they generally include those with 13 or more carbons. Branched alkanes generally include those with 22 or more carbons, since their melting points are often lower than linear alkanes, given the same number of carbon atoms.

Examples of commercially available hydrocarbon products include PARLEAM 6 (NOF Corp.).

[0157]

The blood modifying agent has been found to have at least function of lowering blood viscosity and surface tension, which will be considered in detail in the examples. Menstrual blood to be absorbed by the

absorbent article contains proteins of the endometrial wall, for example, unlike ordinary blood, which act to bind together blood cells, such that the blood cells form a rouleau state. The menstrual blood to be absorbed by the absorbent article therefore tends to have high viscosity, and if the top sheet is a nonwoven fabric of woven fabric, the menstrual blood becomes clogged between the fibers creating a residual sticky feel for the wearer, while the menstrual blood also diffuses on the surface of the top sheet and tends to leak.

Also, in the absorbent article of this disclosure, the blood modifying agent has a melting point of no higher than about 45°C, and therefore, whether liquid or solid at ordinary temperature (25°C) , when it contacts with body fluid at approximately 30-40°C, it liquefies (or is a liquid) and readily dissolves in the body fluid.

[0158]

Also, the blood modifying agent which has an IOB of about 0.00 to 0.60 has high organicity and readily infiltrates between blood cells, and it therefore

stabilizes the blood cells and can prevent formation of a rouleau structure by the blood cells.

Since the blood modifying agent stabilizes blood cells and helps to prevent formation of a rouleau

structure by the blood cells, it facilitates absorption of menstrual blood by the absorbent body. For example, with an absorbent article comprising an acrylic super- absorbent polymer, or SAP, absorption of menstrual blood is known to lead to covering of the SAP surface by rouleau-formed blood cells and inhibition of the

absorption performance of the SAP, but presumably

stabilization of the blood cells allows the absorption performance of the SAP to be exhibited more easily. In addition, the blood modifying agent which has high affinity with erythrocytes protects the erythrocyte membranes, and therefore may minimize destruction of the erythrocytes .

[0159]

The blood modifying agent preferably has a weight- average molecular weight of no greater than about 2,000, and more preferably it has a weight-average molecular weight of no greater than about 1,000. This is because a high weight-average molecular weight will make it

difficult to lower the viscosity of the blood modifying agent to an appropriate viscosity for coating, and may require dilution with a solvent. In addition, a high number-average molecular weight will create tack in the blood modifying agent and may produce an unpleasant feeling for the wearer. The absorbent article according to at least one embodiment described above may incorporate one or more of the following modifications.

(1) As shown in Fig. 5(a), the absorbent article 1A may comprise an auxiliary sheet 9 between the top sheet 2 and absorbent body 4. The auxiliary sheet 9 is used to speed up absorption of menstrual blood from the skin facing side of the absorbent body 4 by causing menstrual blood of the wearer that has been excreted into the top sheet 2 to diffuse in the planar direction, and to increase the cushioning property of the absorbent article 1A. The auxiliary sheet 9 may employ a hydrophilic liquid-permeable material such as a woven fabric,

nonwoven fabric, porous plastic, fluff pulp or the like.

[0161]

The auxiliary sheet 9 may be bonded to the top sheet 2 and absorbent body 4 using an adhesive such as a hot- melt adhesive. This will allow menstrual blood of the wearer to be rapidly absorbed by the top sheet 2 and migrate into the absorbent body 4. A material with a higher basis weight and higher density than the top sheet 60 may be used in the auxiliary sheet 9. This can increase the rate of migration of menstrual blood from the top sheet 2 into the auxiliary sheet 9.

[0162]

As shown in Fig. 5(b), an auxiliary sheet 9 may be provided between the top sheet 2 and absorbent body 4 even at the interior walls of the through-holes 10. This can increase the speed of diffusion of menstrual blood excreted by the wearer throughout the entirety of the interior walls of the through-holes 10, and increase the absorption rate at which menstrual blood is absorbed into the absorbent body 2.

[0163]

The blood modifying agent coated on the top sheet 2 covering the interior walls of the through-holes 10 migrates from the top sheet 2 into the auxiliary sheet 9. Thus, coating of the blood modifying agent on the top sheet 2 covering the interior walls of the through-holes 10 allows the blood modifying agent to be coated on the auxiliary sheet 9. By coating the blood modifying agent on the auxiliary sheet 9 that covers the interior of the through-holes 10, menstrual blood penetrating the

through-holes 10 more rapidly migrates from the top sheet 2 to the absorbent body 4, and is more rapidly absorbed into the absorbent body 4.

[0164]

Any of the aforementioned embodiments may also be applied in combination with the modifications. The modifications may also be applied in combination with each other.

[0165]

The explanation provided above is merely for

illustration, and the invention is in no way restricted by the described embodiments.

[Examples]

[0166]

By the following examples it was confirmed that the blood modifying agent lowers the viscosity and surface tension of menstrual blood and allows menstrual blood to rapidly migrate from the top sheet 2 into the absorbent body 4. Some examples of the invention will now be explained, with the understanding that the invention is not meant to be limited to the examples.

[0167]

[Example 1]

[Evaluation of rewetting rate and absorbent body

migration rate]

[Data of blood modifying agents]

A commercially available sanitary napkin was

prepared. The sanitary napkin was formed from a top sheet, formed of a hydrophilic agent-treated air-through nonwoven fabric (composite fiber composed of polyester and polyethylene terephthalate, basis weight: 35 g/m²) , an auxiliary sheet, formed of an air-through nonwoven fabric (composite fiber composed of polyester and polyethylene terephthalate, basis weight: 30 g/m²) , an absorbent body comprising pulp (basis weight: 150-450 g/m², increased at the center section) , an acrylic super-absorbent polymer (basis weight: 15 g/m²) and tissue as a core wrap, a water-repellent agent-treated side sheet, and a back sheet composed of a polyethylene film.

[0168]

The blood modifying agents used for the experiment are listed below.

[ (ai) Ester of a chain hydrocarbon tetraol and at least one fatty acid]

^• UNISTAR H-408BRS, product of NOF Corp.

Tetrapentaerythritol 2-ethylhexanoate, weight- average molecular weight: approximately 640

^• UNISTAR H-2408BRS-22, product of NOF Corp.

Mixture of tetrapentaerythritol 2-ethylhexanoate and di-neopentyl 2-ethylhexanoate glycol (58:42, mass ratio), weight-average molecular weight: approximately 520

[0169]

[ (a₂) Ester of a chain hydrocarbon triol and at least one fatty acid]

^• Cetiol SB45DEO, Cognis Japan

Glycerin and fatty acid triester, with oleic acid or stearylic acid as the fatty acid.

^• SOY42, product of NOF Corp.

Glycerin and fatty acid triester with C_i4 fatty

acid:Ci6 fatty acid:Ci₈ fatty acid:C₂o fatty acid

(including both saturated fatty acids and unsaturated fatty acids) at a mass ratio of about 0.2:11:88:0.8, weight-average molecular weight: 880

[0170]

^• Tri-C2L oil fatty acid glyceride, product of NOF Corp.

Glycerin and fatty acid triester with C₈ fatty acid:Cio fatty acid:Ci₂ fatty acid at a mass ratio of about 37:7:56, weight-average molecular weight: approximately 570

^• Tri-CL oil fatty acid glyceride, product of NOF Corp.

Glycerin and fatty acid triester with C₈ fatty

acid:Ci2 fatty acid at a mass ratio of about 44:56, weight-average molecular weight: approximately 570

[0171]

^• PANACET 810s, product of NOF Corp.

Glycerin and fatty acid triester with C₈ fatty acid:Cio fatty acid at a mass ratio of about 85:15, weight-average molecular weight: approximately 480

^• PANACET 800, product of NOF Corp.

Glycerin and fatty acid triester with octanoic acid (C₈) as the entire fatty acid portion, weight-average molecular weight: approximately 470

[0172]

^• PANACET 800B, product of NOF Corp.

Glycerin and fatty acid triester with 2- ethylhexanoic acid (C₈) as the entire fatty acid portion, weight-average molecular weight: approximately 470

· NA36, product of NOF Corp.

Glycerin and fatty acid triester with Cie fatty acid:Ci8 fatty acid:C₂o fatty acid (including both

saturated fatty acids and unsaturated fatty acids) at a mass ratio of about 5:92:3, weight-average molecular weight: approximately 880

[0173]

^• Tri-coconut fatty acid glyceride, product of NOF Corp.

Glycerin and fatty acid triester with C₈ fatty acid:Cio fatty acid:Ci₂ fatty acid:Ci₄ fatty acid:Ci₆ fatty acid (including both saturated fatty acids and

unsaturated fatty acids) at a mass ratio of about

4:8:60:25:3, weight-average molecular weight: 670

[0174]

^• Caprylic acid diglyceride, product of NOF Corp.

Glycerin and fatty acid diester with octanoic acid as the fatty acid, weight-average molecular weight:

approximately 340 [0175]

[ (a₃) Ester of a chain hydrocarbon diol and at least one fatty acid]

• COMPOL BL, product of NOF Corp.

Dodecanoic acid (Ci₂) monoester of butylene glycol, weight-average molecular weight: approximately 270

• COMPOL BS, product of NOF Corp.

Octadecanoic acid (Cig) monoester of butylene glycol, weight-average molecular weight: approximately 350

• UNISTAR H-208BRS, product of NOF Corp.

Neopentylglycol di-2-ethylhexanoate, weight-average molecular weight: approximately 360.

[0176]

[ (c₂) Ester of a chain hydrocarbon tricarboxylic acid, hydroxy acid, alkoxy acid or oxoacid with 3 carboxyl groups, and at least one aliphatic monohydric alcohol]

^• Tributyl O-acetylcitrate, product of Tokyo Kasei Kogyo Co., Ltd.

Weight-average molecular weight: approximately 400

[0177]

[ (c₃) Ester of a chain hydrocarbon dicarboxylic acid, hydroxy acid, alkoxy acid or oxoacid with 2 carboxyl groups, and at least one aliphatic monohydric alcohol]

^• Dioctyl adipate, product of Wako Pure Chemical

Industries, Ltd.

Weight-average molecular weight: approximately 380

[0178]

[ (d₃) Ester of a fatty acid and an aliphatic monohydric alcohol]

^• ELECTOL WE20, product of NOF Corp.

Ester of dodecanoic acid (C12) and dodecyl alcohol (C12) , weight-average molecular weight: approximately 360

^• ELECTOL WE40, product of NOF Corp.

Ester of tetradecanoic acid (Ci₄) and dodecyl alcohol (C12) , weight-average molecular weight: approximately 390

[0179]

[ (ei) Polyoxy C₂-C₆ alkylene glycol] • UNIOL D-1000, product of NOF Corp.

Polypropylene glycol, weight-average molecular weight: approximately 1,000

• UNIOL D-1200, product of NOF Corp.

Polypropylene glycol, weight-average molecular weight: approximately 1,160

■ UNIOL D-3000, product of NOF Corp.

Polypropylene glycol, weight-average molecular weight: approximately 3,000

[0180]

• UNIOL D-4000, product of NOF Corp.

Polypropylene glycol, weight-average molecular weight: approximately 4,000

• UNIOL PB500, product of NOF Corp.

Polybutylene glycol, weight-average molecular weight: approximately 500

• UNIOL PB700, product of NOF Corp.

Polyoxybutylenepolyoxypropylene glycol, weight- average molecular weight: approximately 700

[0181]

• UNIOL PB1000R, product of NOF Corp.

Polybutylene glycol, weight-average molecular weight: approximately 1,000

[ (e2) Ester of a polyoxy C2-C6 alkylene glycol and at least one fatty acid]

^• WILBRITE cp9, product of NOF Corp.

Polybutylene glycol compound with OH groups at both ends esterified by hexadecanoic acid (Ci₆) , weight-average molecular weight: approximately 1,150

[ (e₃) Ether of polyoxy C₂-C₆ alkylene glycol and at least one fatty acid]

• UNILUBE MS-70K, product of NOF Corp.

Stearyl ether of polypropylene glycol, approximately 15 repeating units, weight-average molecular weight:

approximately 1,140

[0182]

[ (es) Ether of a polyoxy C₂-C₆ alkylene glycol with chain hydrocarbon tetraol, chain hydrocarbon triol or chain hydrocarbon diol]

• UNILUBE 5TP-300KB

Polyoxyethylenepolyoxypropylene pentaerythritol ether, produced by addition of 5 mol of ethylene oxide and 65 mol of propylene oxide to 1 mol of

pentaerythritol, weight-average molecular weight: 4,130

[0183]

^• UNIOL TG-3000, product of NOF Corp.

Glyceryl ether of polypropylene glycol,

approximately 16 repeating units, weight-average

molecular weight: approximately 3,000

^• UNIOL TG-4000, product of NOF Corp.

Glyceryl ether of polypropylene glycol,

approximately 16 repeating units, weight-average

molecular weight: approximately 4,000

[0184]

[ (fi) Chain alkane]

^• PARLEA 6, product of NOF Corp.

Branched hydrocarbon, produced by copolymerization of liquid isoparaffin, isobutene and n-butene followed by hydrogen addition, polymerization degree: approximately 5-10, weight-average molecular weight: approximately 330

[0185]

[Other components]

^• NA50, product of NOF Corp.

Glycerin and fatty acid triester obtained by

addition of hydrogen to NA36 for reduced proportion of double bonds from unsaturated fatty acid starting

material, weight-average molecular weight: approximately 880

^• (Caprylic acid/capric acid) monoglyceride, product of NOF Corp.

Glycerin and fatty acid monoester, with octanoic acid (C₈) and decanoic acid (Ci₀) at a mass ratio of about

85:15, weight-average molecular weight: approximately 220

^• Monomuls 90-L2 lauric acid monoglyceride, product of Cognis Japan

[0186]

• Isopropyl citrate, product of Tokyo Kasei Kogyo Co., Ltd.

Weight-average molecular weight: approximately 230

• Diisostearyl malate

Weight-average molecular weight: approximately 640

• UNIOL D-400, product of NOF Corp.

Polypropylene glycol, weight-average molecular weight: approximately 400

[0187]

• PEG1500, product of NOF Corp.

Polyethylene glycol, weight-average molecular weight: approximately 1,500-1,600

· NONION S-6, product of NOF Corp.

Polyoxyethylene monostearate, approximately 7 repeating units, weight-average molecular weight:

approximately 880

^• WILBRITE s753, product of NOF Corp.

Polyoxyethylenepolyoxypropylene polyoxybutylene glycerin, weight-average molecular weight: approximately

960

[0188]

^• UNIOL TG-330, product of NOF Corp.

Glyceryl ether of polypropylene glycol,

approximately 6 repeating units, weight-average molecular weight: approximately 330

^• UNIOL TG-1000, product of NOF Corp.

Glyceryl ether of polypropylene glycol,

approximately 16 repeating units, weight-average

molecular weight: approximately 1,000

[0189]

^• UNILUBE DGP-700, product of NOF Corp.

Diglyceryl ether of polypropylene glycol,

approximately 9 repeating units, weight-average molecular weight: approximately 700

^• UNIOX HC60, product of NOF Corp. Polyoxyethylene hydrogenated castor oil, weight- average molecular weight: approximately 3,570

• Vaseline, product of Cognis Japan

Petroleum-derived hydrocarbon, semi-solid

[0190]

The IOBs, melting points and water solubilities of the samples are shown in Table 2.

The water solubility was measured by the method described above, and samples that dissolved 24 hours after addition of 20.0 g to 100 g of desalted water were evaluated as "20 g<", and samples of which 0.05 g

dissolved in 100 g of desalted water but 1.00 g did not dissolve were evaluated as 0.05-1.00 g.

For the melting point, "<45" indicates a melting point of below 45°C.

[0191]

The skin contact surface of the top sheet of the sanitary napkin was coated with the aforementioned blood modifying agent. Each blood modifying agent was used directly, when the blood modifying agent was liquid at room temperature, or when the blood modifying agent was solid at room temperature it was heated to its melting point of +20°C, and a control seam H A gun was used for atomization of the blood modifying agent and coating onto the entire skin contact surface of the top sheet to a basis weight of about 5 g/m².

[0192]

Fig. 6 is an electron micrograph of the skin contact surface of a top sheet in a sanitary napkin (No.2-5) wherein the top sheet comprises tri-C2L oil fatty acid glycerides. As clearly seen in Fig. 6, the tri-C2L oil fatty acid glycerides are present on the fiber surfaces as fine particulates.

In accordance with the above procedures, the

rewetting rate and absorber migration rate were measured.

The results are shown below in Table 2.

[0193] [Test methods]

An acrylic board with an opened hole (200 mm x 100 mm, 125 g, with a 40 mm x 10 mm hole opened at the center) was placed on a top sheet comprising each blood modifying agent, and 3 g of horse EDTA blood at 37±1°C (obtained by adding appropriate amount of

ethylenediaminetetraacetic acid (hereunder, "EDTA") to horse blood to prevent coagulation) was dropped through the hole using a pipette (once) , and after 1 minute, 3 g of horse EDTA blood at 37±1°C was again added dropwise through the acrylic board hole with a pipette (twice) .

[0194]

After the second dropping of blood, the acrylic board was immediately removed and 10 sheets of filter paper (Advantec Toyo Kaisha, Ltd, Qualitative Filter

Paper No.2, 50 mm x 35 mm) were placed on the location where the blood had been dropped, and then a weight was placed thereover to a pressure of 30 g/cm². After 1 minute, the filter paper was removed and the "rewetting rate" was calculated by the following formula.

Rewetting rate (%)

= 100 x (filter paper mass after test - initial filter paper mass) /6

[0195]

In addition to the rewetting rate evaluation, the

"absorbent body migration rate" was also measured as the time until migration of blood from the top sheet to the absorbent body after the second dropping of blood. The absorbent body migration rate is the time from

introducing the blood onto the top sheet, until the redness of the blood could be seen on the surface and in the interior of the top sheet.

The results for the rewetting rate and absorbent body migration rate are shown below in Table 2.

[0196]

Then the whiteness of the skin contact surface of the top sheet after the absorbent body migration rate test was visually evaluated on the following scale.

VG (Very Good) : Virtually no redness of blood remaining, and no clear delineation between areas with and without blood.

G (Good) : Slight redness of blood remaining, but difficult to delineate between areas with and without blood.

F (Fair) : Slight redness of blood remaining, areas with blood discernible.

P (Poor) : Redness of blood completely remaining. The results are summarized below in Table 2.

[0197]

Table 2

[0198]

Table 2 (cont . )

[0199]

In the absence of a blood modifying agent, the rewetting rate was 22.7% and the absorbent body migration rate was greater than 60 seconds, but the glycerin and fatty acid triesters all produced rewetting rates of no greater than 7.0% and absorbent body migration rates of no longer than 8 seconds, and therefore significantly improved the absorption performance. Of the glycerin and fatty acid triesters, however, no great improvement in absorption performance was seen with NA50 which had a melting point of above 45°C.

[0200]

Similarly, the absorption performance was also significantly improved with blood modifying agents having an IOB of about 0.00-0.60, a melting point of no higher than about 45°C and a water solubility of no greater than about 0.05 g in 100 g of water at 25°C. Rewetting rates of no greater than 7.9% and absorbent body migration rates of no longer than 15 seconds were achieved.

[0201]

Next, several volunteer subjects were asked to wear sanitary napkins Nos. (2-1) - (2-47) , and the obtained responses indicated that with the sanitary napkins comprising blood modifying agents Nos. (2-1) - (2-32) , the top sheets had no sticky feel and the top sheets were smooth, even after absorption of menstrual blood

[0202]

Also, with sanitary napkins Nos. (2-1) - (2-32) , and particularly with sanitary napkins that comprised blood modifying agents Nos. (2-1) - (2-11) , (2-15 )- (2-19) and (2-

32) , the skin contact surfaces of the top sheets after absorption of menstrual blood had not been reddened by the blood and the unpleasantness was minimal.

[0203]

[Example 2]

The rewetting rate was evaluated for blood from different animals in accordance with the above

procedures. The following blood was used for the test. [Animal species]

( 1 ) Human

(2) Horse

(3) Sheep

[0204]

[Types of blood]

^• Defibrinated blood: blood sampled and agitated together with glass beads in an Erlenmeyer flask for approximately

5 minutes.

^• EDTA blood: 65 mL of venous blood with addition of 0.5 mL of a 12% EDTA-2K isotonic sodium chloride solution.

[0205]

[Fractionation]

Serum or blood plasma: Supernatant obtained after centrifugation of defibrinated blood or EDTA blood for 10 minutes at room temperature at about 1900 G.

Blood cells: Obtained by removing the serum from the blood, washing twice with phosphate buffered saline

(PBS) , and adding phosphate buffered saline to the removed serum portion.

[0206]

An absorbent article was produced in the same manner as Example 2, except that the tri-C2L oil fatty acid glyceride was coated at a basis weight of about 5 g/m², and the rewetting rate of each of the aforementioned blood samples was evaluated. Measurement was performed 3 times for each blood sample, and the average value was recorded.

The results are shown in Table 3 below.

[0207] Table 3

[0208]

The same trend was seen with human and sheep blood as with the horse EDTA blood, as obtained in Example 2.

A similar trend was also observed with defibrinated blood and EDTA blood.

[0209]

[Example 3]

[Evaluation of blood retention]

The blood retention was evaluated for a top sheet comprising a blood modifying agent and a top sheet comprising no blood modifying agent.

[0210]

[Test methods]

(1) A tri-C2L oil fatty acid glyceride was atomized on the skin contact surface of a top sheet formed from an air-through nonwoven fabric (composite fiber composed of polyester and polyethylene terephthalate, basis weight: 35 g/m²) , using a control seam HMA gun, for coating to a basis weight of about 5 g/m². For comparison, there was also prepared a sheet without coating with the tri-C2L oil fatty acid glyceride. Next, both the tri-C2L oil fatty acid glyceride-coated top sheet and the non-coated top sheet were cut to a size of 0.2 g, and the mass (a) of the cell strainer + top sheet was precisely measured.

[0211]

(2) After adding about 2 mL of horse EDTA blood from the skin contact surface side, it was allowed to stand for 1 minute.

(3) The cell strainer was set in a centrifuge tube, and subjected to spin-down to remove the excess horse EDTA blood.

(4) The mass (b) of the top sheet containing the cell strainer + horse EDTA blood was measured.

(5) The initial absorption (g) per 1 g of top sheet was calculated by the following formula.

Initial absorption = [mass (b) - mass (a)]/0.2

(6) The cell strainer was again set in the

centrifuge tube and centrxfuged at room temperature for 1 minute at approximately 1,200 G.

[0212]

(7) The mass (c) of the top sheet containing the cell strainer + horse EDTA blood was measured.

(8) The post-test absorption (g) per 1 g of top sheet was calculated by the following formula.

Post-test absorption = [mass (c) - mass (a)]/0.2

(9) The blood retention (%) was calculated according to the following formula.

Blood retention (%) = 100 x post-test

absorption/initial absorption

The measurement was conducted 3 times, and the average value was recorded.

The results are shown in Table 4 below.

[0213] Table 4

[0214]

The top sheets comprising blood modifying agents had low blood retentions, suggesting that blood rapidly migrated into the absorbent body after absorption.

[0215]

[Example 4]

[Viscosity of blood containing blood modifying agent]

The viscosity of the blood modifying agent- containing blood was measured using a Rheometric

Expansion System ARES (Rheometric Scientific, Inc.).

After adding 2 mass% of PANACET 810s to horse

defibrinated blood, the mixture was gently agitated to form a sample, the sample was placed on a 50 mm-diameter parallel plate, with a gap of 100 μπι, and the viscosity was measured at 37±0.5°C. The sample was not subjected to a uniform shear rate due to the parallel plate, but the average shear rate indicated by the device was 10 s^-1.

[0216]

The viscosity of the horse defibrinated blood containing 2 mass% PANACET 810s was 5.9 mPa-s, while the viscosity of the horse defibrinated blood containing no blood modifying agent was 50.4 mPa-s. Thus, the horse defibrinated blood containing 2 massl PANACET 810s clearly had an approximately 90% lower viscosity than the blood containing no blood modifying agent.

It is known that blood contains components such as blood cells and has thixotropy, and it has been found that the blood modifying agent of this disclosure can lower blood viscosity in the low viscosity range.

Lowering the blood viscosity presumably allows absorbed menstrual blood to rapidly migrate from the top sheet to the absorbent body.

[0217]

In order for the blood modifying agent to cause absorbed menstrual blood to rapidly migrate from the top sheet into the absorbent body, when the blood modifying agent is added at 2 mass% to the horse defibrinated blood and the viscosity is measured under conditions of 37°C and a shear rate of 10 s^-1, the viscosity of the horse

defibrinated blood is preferably reduced by at least 50%, more preferably reduced by at least 60%, even more preferably reduced by at least 70% and most preferably reduced by at least 80%, compared to before the addition.

[0218]

[Example 5]

[Photomicrograph of blood modifying agent-containing blood]

Menstrual blood was sampled from healthy volunteers onto Saran wrap, and PANACET 810s dispersed in a 10-fold mass of phosphate-buffered saline was added to a portion thereof to a PANACET 810s concentration of 1 mass%. The menstrual blood was dropped onto a slide glass, a cover glass was placed thereover, and the state of the

erythrocytes was observed with an optical microscope. A photomicrograph of menstrual blood containing no blood modifying agent is shown in Fig. 7(a), and a

photomicrograph of menstrual blood containing PANACET

810s is shown in Fig. 7(b).

[0219]

As shown Fig. 7, it is seen that the erythrocytes formed aggregates such as rouleaux in the menstrual blood containing no blood modifying agent, while the

erythrocytes were stably dispersed in the menstrual blood containing PANACET 810s. This suggests that the blood modifying agent functions to stabilize erythrocytes in blood.

[0220]

[Example 6] [Surface tension of blood containing blood modifying agent]

The surface tension of blood containing a blood modifying agent was measured by the pendant drop method, using a Drop Master500 contact angle meter by Kyowa Interface Science Co., Ltd. The surface tension was measured after adding a prescribed amount of blood modifying agent to sheep defibrinated blood, and

thoroughly shaking.

The measurement was accomplished automatically with a device, and the surface tension γ was determined by the following formula (see Fig. 8) .

[0221]

γ = g x p x (de)² l/H

g: Gravitational constant

1/H: Correction factor determined from ds/de

p : Density

de: Maximum diameter

ds: Diameter at location of increase by de from dropping edge

[0222]

The density p was measured at the temperatures listed in Table 5, according to JIS K 2249-1995, "Density test methods and density/mass/volume conversion tables", "5. Vibrating density test method".

The measurement was accomplished using a DA-505 by Kyoto Electronics Co., Ltd.

The results are shown in Table 5 below.

[0223] Table 5

[0224]

Table 5 shows that the blood modifying agent can lower the surface tension of blood despite its very low solubility in water, as seen by a water solubility of about 0.00-about 0.05 g in 100 g of water at 25°C.

Lowering the surface tension of blood presumably allows absorbed blood to rapidly migrate from the top sheet to the absorbent body, without being retained between the top sheet fibers.

[0225]

This disclosure relates to the following and any combination thereof:

[Jl]

An absorbent article comprising a liquid-permeable top sheet provided on the skin facing side, a liquid- impermeable back sheet provided on the non-skin facing side and a liquid-retaining absorbent body situated between the top sheet and back sheet and having through- holes running through the skin facing side and the non- skin facing side, wherein:

the top sheet at least partially covers the interior walls of through-holes of the absorbent body; and

the top sheet at least partially covering the interior walls of through-holes is coated with a blood modifying agent,

the blood modifying agent having an IOB of 0.00- 0.60, a melting point of no higher than 45°C and a water solubility of no greater than 0.05 g in 100 g of water at 25°C.

[Jla]

An absorbent article according to Jl, wherein the top sheet completely covers the interior walls of the through-holes of the absorbent body.

[Jib]

An absorbent article according to Jl or Jla, wherein a nonwoven fabric is used for the top sheet.

[Jlc]

An absorbent article according to Jib wherein the size of the fibers of the nonwoven fabric is about 1.1- 8.8 dtex.

[Jld]

An absorbent article according to Jib or Jlc wherein an inorganic filler is added to the fibers of the top sheet.

[Jle]

An absorbent article according to Jld, wherein the inorganic filler is titanium oxide, barium sulfate or calcium carbonate, preferably titanium oxide.

[Jlf]

An absorbent article according to any of Jl-Jle, wherein the back sheet is composed of a resin film with a basis weith for 15-30 g/m², for example composed mainly of a low-density polyethylene resin.

[J2]

An absorbent article according to any of Jl-Jle, which is further provided with a auxiliary sheet between the top sheet and the absorbent body at the interior walls of through-holes of the absorbent body,

wherein the blood modifying agent is coated on the auxiliary sheet.

[J3]

An absorbent article according to any of J1-J2, wherein the number of through-holes per 1 cm² on the skin facing side of the absorbent body is 1 to 10.

[J3a]

An absorbent article according to J3, wherein the number of through-holes per 1 cm² on the skin facing side of the absorbent body is 1 to 5.

[J4]

An absorbent article according to any one of Jl to 3, wherein the open area of the through-holes of the absorbent body is 0.01 to 10 mm².

[J4a]

An absorbent article according to J4, wherein the open area of the through-holes of the absorbent body is 0.1 to 2.5 mm².

[J5]

The absorbent article according to any one of Jl-

J4a, wherein the coating basis weight of the blood modifying agent on the top sheet is 1-30 g/m², preferably 3-10 g/m².

[J5a]

An absorbent article according to J6, wherein the vapor pressure of the blood modifying agent is about 0.00-0.01 Pa, preferably about 0.000-0.001 Pa and more preferably about 0.0000-0.0001 Pa, at 1 atmosphere, 25°C, or at 1 atmosphere, 40°C.

[J5b]

The absorbent article according to any one of Jl to J5a, wherein the blood modifying agent is selected from the group consisting of following items (i)-(iii), and any combination thereof:

(i) a hydrocarbon;

hydrocarbon moiety; and

hydrocarbon moiety, and (iii-3) one or more groups each selected from the group consisting of carboxyl group (- COOH) and hydroxyl group (-OH) substituting a hydrogen of the hydrocarbon moiety;

with the proviso that when 2 or more oxy groups are inserted in the compound of (ii) or (iii) , the oxy groups are not adjacent.

[J6]

The absorbent article according to any one of Jl to J5b, wherein the blood modifying agent is selected from the group consisting of following items (i')-(iii'), and any combination thereof:

(i') a hydrocarbon;

(ii¹) a compound having (ii'-l) a hydrocarbon moiety, and (ii'-2) one or more bonds each selected from the group consisting of carbonyl bond (-CO-) , ester bond (-COO-), carbonate bond (-OCOO-) , and ether bond (-0-) inserted between a C-C single bond of the hydrocarbon moiety; and

(iii') a compound having (iii'-l) a hydrocarbon moiety, (iii¹ -2) one or more bonds each selected from the group consisting of carbonyl bond (-CO-) , ester bond (- COO-), carbonate bond (-OCOO-) , and ether bond (-0-) inserted between a C-C single bond of the hydrocarbon moiety, and (iii¹ -3) one or more groups each selected from the group consisting of carboxyl group (-COOH) and hydroxyl group (-OH) substituting a hydrogen on the hydrocarbon moiety;

with the proviso that when 2 or more same or different bonds are inserted in the compound of (ii') or (iii¹), the bonds are not adjacent.

[J7]

The absorbent article according to any one of Jl to

6, wherein the blood modifying agent is selected from the group consisting of following items (A) -(F), and any combination thereof:

(B) an ether of (Bl) a compound having a chain hydrocarbon moiety and 2-4 hydroxyl groups substituting hydrogens on the chain hydrocarbon moiety and (B2) a compound having a chain hydrocarbon moiety and 1 hydroxyl group substituting a hydrogen on the chain hydrocarbon moiety;

(C) an ester of (Cl) a carboxylic acid, hydroxy acid, alkoxy acid or oxoacid comprising a chain

(D) a compound having a chain hydrocarbon moiety and one bond selected from the group consisting of an ether bond (-0-), carbonyl bond (-CO-), ester bond (-COO-) and carbonate bond (-OCOO-) inserted between a C-C single bond of the chain hydrocarbon moiety;

(E) a polyoxy C₂-C₆ alkylene glycol, or alkyl ester or alkyl ether thereof; and

(F) a chain hydrocarbon.

[J8]

The absorbent article according to any one of Jl to 7, wherein the blood modifying agent is selected from the group consisting of (ai) esters of chain hydrocarbon tetraols and fatty acids, (a2) esters of chain hydrocarbon triols and fatty acids, (a₃) esters of chain hydrocarbon diols and fatty acids, (bi) ethers of chain hydrocarbon tetraols and aliphatic monohydric alcohols, (b2) ethers of chain hydrocarbon triols and aliphatic monohydric alcohols, (b₃) ethers of chain hydrocarbon diols and aliphatic monohydric alcohols, (ci) esters of chain hydrocarbon tetracarboxylic acids, hydroxy acids, alkoxy acids or oxoacids with 4 carboxyl groups, and aliphatic monohydric alcohols, (C2) esters of chain hydrocarbon tricarboxylic acids, hydroxy acids, alkoxy acids or oxoacids with 3 carboxyl groups, and aliphatic monohydric alcohols, (c₃) esters of chain hydrocarbon dicarboxylic acids, hydroxy acids, alkoxy acids or oxoacids with 2 carboxyl groups, and aliphatic monohydric alcohols, (di) ethers of aliphatic monohydric alcohols and aliphatic monohydric alcohols, (d₂) dialkyl ketones, (d₃) esters of fatty acids and aliphatic monohydric alcohols, (d₄) dialkyl carbonates, (ei) polyoxy C₂-6 alkylene glycols, (e₂) esters of polyoxy C₂-6 alkylene glycols and at least one fatty acid, (e₃) ethers of polyoxy C2-6 alkylene glycols and at least one aliphatic monohydric alcohol, (e₄) esters of polyoxy C₂_₆ alkylene glycols with chain hydrocarbon tetracarboxylic acids, chain hydrocarbon tricarboxylic acids or chain hydrocarbon dicarboxylic acids, (es) ethers of polyoxy C₂-6 alkylene glycols with chain hydrocarbon tetraols, chain hydrocarbon triols or chain hydrocarbon diols, and (fx) chain alkanes.

[J8a]

An absorbent article according to any one of Jl to

J8, wherein the blood modifying agent is selected from the group consisting of (ai) esters of chain hydrocarbon tetraols and fatty acids, (a₂) esters of chain hydrocarbon triols and fatty acids, (a₃) esters of chain hydrocarbon diols and fatty acids, (c₂) esters of chain hydrocarbon tricarboxylic acids, hydroxy acids, alkoxy acids or oxoacids with 3 carboxyl groups, and aliphatic monohydric alcohols, (c₃) esters of chain hydrocarbon dicarboxylic acids, hydroxy acids, alkoxy acids or oxoacids with 2 carboxyl groups, and aliphatic monohydric alcohols, (d₃) esters of fatty acids and aliphatic monohydric alcohols, (ei) polyoxy C₂-₆ alkylene glycols, (e₂) esters of polyoxy C₂-6 alkylene glycols and at least one fatty acid, (e₃) ethers of polyoxy C₂_₆ alkylene glycols and at least one aliphatic monohydric alcohol, (e₅) ethers of polyoxy C₂-6 alkylene glycols with chain hydrocarbon tetraols, chain hydrocarbon triols or chain hydrocarbon diols, and (fi) chain alkanes.

fJ8b]

The absorbent article according to any one of Jl to JlOa, wherein the blood modifying agent is selected from the group consisting of:

UNISTAR H-408BRS

UNISTAR H-2408BRS-22

and/or the group consisting of

Cetiol SB45DEO

Soy 42

Tri-C2L oil fatty acid glyceride

Tri-CL oil fatty acid glyceride

PANACET 810s

PANACET 800

PANACET 800B

NA36

Tri-coconut fatty acid glyceride

Caprylic acid diglyceride

and/or the group consisting of

COMPOL BL

COMPOL BS

UNISTAR H-208BRS

and/or the group consisting of

Tributyl O-acetylcitrate

and/or the group consisting of

Dioctyl adipate

and/or the group consisting of

ELECTOL E20

ELECTOL WE40

and/or the group consisting of

UNIOL D-1000

UNIOL D-1200 UNIOL D-3000

UNIOL D-4000

UNIOL PB500

UNIOL PB700

UNIOL PB1000R

and/or the group consisting of

ILBRITE cp9

and/or the group consisting of

UNILUBE MS-70K

and/or the group consisting of

UNILUBE 5TP-300KB

UNIOL TG-3000

UNIOL TG-4000

and/or the group consisting of

PARLEAM 6

all as described hereinabove.

[Explanation of Symbols]

[0226]

This application claims the benefit of Japanese Application No. 2011-218541 the entire disclosure of which is incorporated by reference herein.

Claims

[CLAIM 1]

An absorbent article comprising a liquid-permeable top sheet provided on a skin facing side, a liquid- impermeable back sheet provided on a non-skin facing side and a liquid-retaining absorbent body situated between the top sheet and back sheet and having through-holes running from the skin facing side to the non-skin facing side, Wherein:

the top sheet at least partially covers the interior walls of the through-holes of the absorbent body, and

the top sheet at least partially covering the interior walls of the through-holes is coated with a blood modifying agent,

the blood modifying agent having an Inorganic- Organic Balance of 0.00-0.60, a melting point of no higher than 45°C and a water solubility of no greater than 0.05 g in 100 g of water at 25°C.

[CLAIM 2]

The absorbent article according to claim 1, wherein the top sheet completely covers the interior walls of the through-holes of the absorbent body.

[CLAIM 3]

The absorbent article according to claim 1 or 2, further comprising an auxiliary sheet between the top sheet and the absorbent body at the interior walls of the through-holes of the absorbent body,

wherein the blood modifying agent is coated on the auxiliary sheet.

[CLAIM 4]

The absorbent article according to any one of claims 1 to 3, wherein the number of through-holes per 1 cm² on the skin facing side of the absorbent body is 1 to 10.

[CLAIM 5]

The absorbent article according to any one of claims 1 to 4, wherein the open area of each of the through- holes of the absorbent body is 0.01 to 10 mm².

[CLAIM 6]

The absorbent article according to any one of claims 1 to 5, wherein the blood modifying agent is selected from the group consisting of the following items (i)-

(iii) , and any combination thereof:

(i) a hydrocarbon;

(ii) a compound having (ii-1) a hydrocarbon moiety, and (ii-2) one or more groups each selected from the group consisting of carbonyl group (-CO-) and oxy group

(-0-) inserted between a C-C single bond of the

hydrocarbon moiety; and

(iii) a compound having (iii-1) a hydrocarbon moiety, (iii-2) one or more groups each selected from the group consisting of carbonyl group (-CO-) and oxy group

(-0-) inserted between a C-C single bond of the

wherein when 2 or more oxy groups are inserted in the compound of (ii) or (iii) , the oxy groups are not adjacent.

[CLAIM 7]

The absorbent article according to any one of claims

1 to 6, wherein the blood modifying agent is selected from the group consisting of the following items (i¹)- (iii¹), and any combination thereof:

(i¹) a hydrocarbon;

(ii¹) a compound having at least (ii'-l) a

hydrocarbon moiety, and (ii'-2) one or more bonds each selected from the group consisting of carbonyl bond (-CO- ), at least one ester bond (-COO-) , at least one

carbonate bond (-OCOO-), and at least one ether bond (-0- ) inserted between a C-C single bond of the hydrocarbon moiety; and

(iii') a compound having at least (iii'-l) a hydrocarbon moiety, (iii'-2) one or more bonds each selected from the group consisting of carbonyl bond (-C0- ) , at least one ester bond (-C00-) , at least one

carbonate bond (-0C00-) , and at least one ether bond (-0- ) inserted between a C-C single bond of the hydrocarbon moiety, and (iii'-3) one or more groups each selected from the group consisting of carboxyl group (-C00H) and hydroxyl group (-0H) substituting a hydrogen on the hydrocarbon moiety;

wherein when 2 or more same or different bonds are inserted in the compound of (ii¹) or (iii¹), the bonds are not adjacent.

[CLAIM 8]

The absorbent article according to any one of claims 1 to 7, wherein the blood modifying agent is selected from the group consisting of the following items (A) -(F), and any combination thereof:

(D) a compound having a chain hydrocarbon moiety and one bond selected from the group consisting of an ether bond (-0-) , carbonyl bond (-CO-) , ester bond (-COO-) and carbonate bond (-OCOO-) inserted between a C-C single bond of the chain hydrocarbon moiety;

(F) a chain hydrocarbon.

[CLAIM 9]

The absorbent article according to any one of claims 1 to 8, wherein the blood modifying agent is selected from the group consisting of (ai) esters of chain

hydrocarbon tetraols and at least one fatty acid, (a₂) esters of chain hydrocarbon triols and at least one fatty acid, (a₃) esters of chain hydrocarbon diols and at least one fatty acid, (bj.) ethers of chain hydrocarbon tetraols and at least one aliphatic monohydric alcohol, (b₂) ethers of chain hydrocarbon triols and at least one aliphatic monohydric alcohol, (b₃) ethers of chain hydrocarbon diols and at least one aliphatic monohydric alcohol, (ci) esters of chain hydrocarbon tetracarboxylic acids, hydroxy acids, alkoxy acids or oxoacids with 4 carboxyl groups, and at least one aliphatic monohydric alcohol, (c₂) esters of chain hydrocarbon tricarboxylic acids, hydroxy acids, alkoxy acids or oxoacids with 3 carboxyl groups, and at least one aliphatic monohydric alcohol, (c₃) esters of chain hydrocarbon dicarboxylic acids, hydroxy acids, alkoxy acids or oxoacids with 2 carboxyl groups, and at least one aliphatic monohydric alcohol, (di) ethers of aliphatic monohydric alcohols and aliphatic monohydric alcohols, (d₂) dialkyl ketones, (d₃) esters of fatty acids and aliphatic monohydric alcohols, (d₄) dialkyl

carbonates, (e_x) polyoxy C₂-₆ alkylene glycols, (e₂) esters of polyoxy C₂-6 alkylene glycols and at least one fatty acid, (e₃) ethers of polyoxy C₂-₆ alkylene glycols and at least one aliphatic monohydric alcohol, (e₄) esters of polyoxy C₂_₆ alkylene glycols with chain hydrocarbon tetracarboxylic acids, chain hydrocarbon tricarboxylic acids or chain hydrocarbon dicarboxylic acids, (e₅) ethers of polyoxy C2-6 alkylene glycols with chain hydrocarbon tetraols, chain hydrocarbon triols or chain hydrocarbon diols, and (fi) chain alkanes.